Chemodynamic nanomaterials for cancer theranostics

Jingqi Xin1, Caiting Deng1, Omer Aras2, Mengjiao Zhou3*, Chunsheng Wu1* and Feifei An1*

Abstract

It is of utmost urgency to achieve effective and safe anticancer treatment with the increasing mortality rate of cancer. Novel anticancer drugs and strategies need to be designed for enhanced therapeutic efficacy. Fenton- and Fenton-like reaction-based chemodynamic therapy (CDT) are new strategies to enhance anticancer efficacy due to their capacity to generate reactive oxygen species (ROS) and oxygen (O2). On the one hand, the generated ROS can damage the cancer cells directly. On the other hand, the generated O2 can relieve the hypoxic condition in the tumor microenvironment (TME) which hinders efficient photodynamic therapy, radiotherapy, etc. Therefore, CDT can be used together with many other therapeutic strategies for synergistically enhanced combination therapy. The antitumor applications of Fenton- and Fenton-like reaction-based nanomaterials will be discussed in this review, including: (i) producing abundant ROS in-situ to kill cancer cells directly, (ii) enhancing therapeutic efficiency indirectly by Fenton reaction-mediated combination therapy, (iii) diagnosis and monitoring of cancer therapy. These strategies exhibit the potential of CDT-based nanomaterials for efficient cancer therapy.

Keywords: Fenton reaction, Chemodynamic therapy, Theranostics, Hypoxia, Combination therapy

Background

Cancer poses a serious threat to human health and has attracted considerable attention in biomedical research over the past few decades [1]. The mortality rate of cancer increases year by year, making it of utmost urgency to develop even more efficient cancer therapeutic strategies. There are many cancer therapeutic strategies, ranging from traditional strategies such as surgery, chemotherapy, radiotherapy, photodynamic therapy (PDT), to newer strategies such as photothermal therapy (PTT) and immunotherapy [2–6]. Often, the anticancer efficiency of these strategies is limited by low tumor selectivity, systemic toxicity, and adverse reactions, etc. [7].

Besides, many types of cancer gradually develop resistance to traditional therapies [8]. In order to improve the therapeutic effect, novel anticancer drugs and strategies are still desired [9, 10]. Chemodynamic therapy (CDT), which is defined as in-situ treatment via Fenton and Fenton-like reactions, has attracted more and more attention in recent years [11–13]. As a novel modality for cancer treatment, CDT exhibits preferable therapeutic performance and satisfying biosafety [14]. In comparison with traditional therapies, CDT can generate spatiotemporal controllable and tissue depth-unlimited reactive oxygen species (ROS) and oxygen (O2) in response to the high level of hydrogen peroxide (H2O2) in the tumor microenvironment (TME) [14–17].

Fenton and Fenton-like reactions, which generate abundant oxidative •OH or O2, can be triggered by the endogenous H2O2 of cancer cells and catalyzed by transition metal ions or their complexes [18]. While Fenton and Fenton-like reactions are commonly suppressed by the insufficient H2O2 and slightly alkaline conditions of a normal microenvironment, in the acidic TME, metal...
ions can be dissolved from iron or other transition metal ions-based nanomaterials to activate Fenton and Fenton-like reactions [19]. On the one hand, the production of •OH can result in oxidant damage to cellular constituents (proteins, lipids, DNA, et al.), apoptosis or necrosis, and likely cell death [20, 21]. The generated •OH can inhibit tumor growth directly without damaging normal tissue [22]. On the other hand, Fenton and Fenton-like reactions can generate O2 to relieve tumor hypoxia, which can lead to path-breaking enhanced cancer therapeutic combination strategies [23]. It is well known that tumor hypoxia is a result of an insufficient supply but quick oxygen consumption in the fast-growing neoplastic cell population in solid tumors [24, 25]; tumor hypoxia has been implicated as one of the major factors that limits treatment efficacy and that promotes development of resistance in many cancer therapeutic methods [26–28]. Fenton and Fenton-like reactions are important strategies to overcome hypoxia via in-situ production of O2 in the TME [29]. When used with other anticancer strategies, Fenton and Fenton-like reactions can enhance the tumor sensitivity to other anticancer strategies by supplying O2 to the hypoxic TME, resulting in enhanced anticancer efficacy.

Recently, nanotechnology has played a significant role in the development of new targeted tumor diagnosis and therapeutic strategies [30–32]. Emerging Fenton and Fenton-like reaction-based nanomaterials are mainly iron-based, followed by other metal-based nanoparticles (NPs) (including Mn2+, Cu2+, and Ti3+ ions, etc.), and several organic NPs [33–35]. Due to the characteristics of these nanomaterials, including tumor targeting ability, large specific surface area, and high reactivity, they are potent tools for the production of •OH and O2 via Fenton and Fenton-like reactions [36]. With the tumor targeting ability of these nanomaterials, Fenton- and Fenton-like reactions-based NPs can lead to gains in therapeutic efficiency while causing only a low level of side effects [11]. Herein, we present an overview of recent findings related to Fenton- and Fenton-like reaction-based nanomaterials, which can be categorized into three groups for different applications in cancer theranostics: (i) producing abundant ROS in situ to kill cancer cells directly, (ii) enhancing the therapeutic efficiency indirectly by Fenton- and Fenton-like reaction-mediated combination therapy, (iii) diagnosis and monitoring of cancer therapy (Scheme 1).

**Fenton and Fenton-like reactions for in-situ ROS generation**

Cancer cells typically already have more ROS compared with normal cells due to their increased metabolism, increased receptor signaling, and malfunction of oncogene activity and mitochondria. ROS at low levels play an important role in supporting cellular life cycles [37]. By contrast, high concentrations of ROS damage cellular constituents [38]. In particular, •OH radicals cause more serious damage to cancer cells than other ROS, which is ascribed to their relatively stronger reactivity with cellular constituents [39]. Fenton and Fenton-like reactions triggered by iron or other metal ions exhibit the ability to generate abundant •OH by decomposing the endogenous H2O2 in cancer cells [40, 41]. Therefore, Fenton and Fenton-like reactions can be used to treat cancer by in-situ production of abundant ROS to kill cancer cells directly [42], but first, the selection of the catalyst is pivotal [43]. Several nanomaterials can efficiently trigger Fenton and Fenton-like reactions, due to their high catalytic efficiency and excellent biocompatibility; these include iron-based nanomaterials, other metal-based nanomaterials (including Mn2+, Cu2+, and Mo3+, etc.), and several organic nanomaterials (Fig. 1) [44–47]. These nanomaterials can serve as efficient catalysts for various theranostic applications (Table 1).

**Iron-based nanomaterials**

According to the Fenton reaction (Eq. 1 and 2), overproduction of H2O2 in the TME can be converted to •OH, •OOH and O2 in the presence of iron ions (Fe2+ and Fe3+) [73, 74].

\[
\text{Fe}^{2+} + \text{H}_2\text{O}_2 \rightarrow \text{Fe}^{3+} + \cdot\text{OH} + \text{OH}^- \quad (1)
\]

\[
\text{Fe}^{3+} + \text{H}_2\text{O}_2 \rightarrow \text{Fe}^{2+} + \cdot\text{OOH} + \text{H}^+ \quad (2)
\]

\[
\text{Fe}^{3+} + \cdot\text{OOH} \rightarrow \text{Fe}^{2+} + \text{O}_2 + \text{H}^+ \quad (3)
\]

The Fenton reaction can be directly catalyzed by iron ions to generate •OH, •OOH, and O2 [75].

Meanwhile, iron ions also play a key role in ferroptosis, in which lipid-based ROS is produced due to the inhibition of system x− and the biosynthesis of glutathione (GSH) [76]. In ferroptosis, the activity of system x− (SLC7A11) is inhibited, resulting in decreased
import of cysteine, GSH depletion, inactivation of the glutathione peroxidase 4 (GPX4), and finally ferroptosis [77, 78]. In addition, the tumor suppressor p53 can negatively regulate histone H2B monoubiquitination levels by promoting the nuclear translocation of the deubiquitinase to inhibit the expression of SLC7A11, leading to ferroptosis [79, 80]. Therefore, in addition to contributing to Fenton reaction-assisted therapy, iron ions can also produce an enhanced treatment effect via ferroptosis [81, 82].

In recent years, diverse efforts based on GSH depletion or H₂O₂ concentration elevation have been made to improve the anticancer efficiency triggered by Fenton and Fenton-like reactions [11, 83, 84]. GSH is overexpressed in many types of cancer cells and can reduce the ROS that are generated by Fenton- and Fenton-like reactions, thereby decreasing the therapeutic effect of CDT [85–87]. Therefore, in one study, the GSH depletion agent, sabutoclax, was loaded into Fe³⁺-containing nanoparticles (NPs) in order to produce the synergistic
effect of Fe\textsuperscript{3+}-mediated Fenton reactions and sabutoclax-induced GSH depletion [51]. In another study, the ROS inducer, β-lapachone, was loaded into the Fe\textsubscript{3}O\textsubscript{4} NPs to produce the synergistic effect of Fe\textsubscript{3}O\textsubscript{4}-mediated Fenton reactions and β-lapachone-induced ROS generation [88]. In addition, several studies have made use of glucose oxidase (GOD), an endogenous enzyme that not only consumes GSH in cancer cells, leading to starvation therapy, but also simultaneously generates plenty of H\textsubscript{2}O\textsubscript{2} to facilitate Fenton and Fenton-like reactions [89, 90]. For example, GOD has been loaded into an adenosine triphosphate (ATP)-responsive Fenton system (GOD@ZIF@MPN) to enhance cancer therapy [91]. The outer shell metal polyphenol network (MPN) of GOD@ZIF@MPN was degraded into Fe\textsuperscript{3+} and tannic acid (TA) and the internal GOD was exposed when internalized into the ATP-overexpressed tumor cells. TA reduced Fe\textsuperscript{3+} to Fe\textsuperscript{2+}, and GOD reacted with endogenous glucose to generate tremendous H\textsubscript{2}O\textsubscript{2} for Fe\textsuperscript{2+}-catalyzed Fenton reaction. The combination of this Fe\textsuperscript{2+}-induced Fenton reaction with ferroptosis synergistically resulted in an improved antitumor effect [92].

In order to further improve Fenton reaction-assisted cancer therapy, one study delivered exogenous H\textsubscript{2}O\textsubscript{2} to the tumor to increase the level of H\textsubscript{2}O\textsubscript{2} in the TME [93]. The liquid H\textsubscript{2}O\textsubscript{2} was loaded in the form of H\textsubscript{2}O\textsubscript{2}/Fe\textsubscript{3}O\textsubscript{4}-PLGA polymersome, in which H\textsubscript{2}O\textsubscript{2} located in the hydrophilic core and Fe\textsubscript{3}O\textsubscript{4} NPs inside the polymersome membrane. Upon exposure to ultrasound, the encapsulated H\textsubscript{2}O\textsubscript{2} was released to react with the packed Fe\textsubscript{3}O\textsubscript{4} NPs to yield •OH via the Fenton reaction, and finally improve the therapeutic efficacy. Another study used the in situ generation of H\textsubscript{2}O\textsubscript{2} to improve Fenton reaction-assisted cancer therapy, whereby H\textsubscript{2}O\textsubscript{2} was supplied from the reaction of CaO\textsubscript{2} and H\textsuperscript{+} [94]. In this study, CaO\textsubscript{2} was integrated into the Fe\textsubscript{3}O\textsubscript{4}@HA-Cy7 NPs by preparing hybrid CaO\textsubscript{2} and Fe\textsubscript{3}O\textsubscript{4} NPs with hyaluronate acid as the stabilizer and Cy7 as a fluorescence tracer. Fe\textsubscript{3}O\textsubscript{4}-mediated Fenton reaction was enhanced by H\textsubscript{2}O\textsubscript{2} supply from the reaction of CaO\textsubscript{2} and H\textsuperscript{+}. In yet another study, E coli MG1655 was engineered with NDH-2

Table 1: Representative Fenton- and Fenton-like reaction-based nanomaterials and their typical applications in cancer theranostics

| Nanomaterials                         | Fenton nanoagents                     | Applications                                      | Refs. |
|---------------------------------------|---------------------------------------|--------------------------------------------------|-------|
| Iron-based nanomaterials              | Dichloroacetic acid@MOF-Fe\textsuperscript{2+} | CDT                                              | [48]  |
|                                       | DOX-ferrocene-inhibitor@β-CD NPs      | CDT-chemotherapy                                 | [49]  |
|                                       | DOX@Pt prodrug-Fe\textsuperscript{3+} NPs | CDT-chemotherapy                                 | [50]  |
|                                       | Fe\textsubscript{3}O\textsubscript{4}/triphenylphosphine/PpIX NPs | CDT-PDT                                          | [51]  |
|                                       | PtFe@Fe\textsubscript{3}O\textsubscript{4} NPs | CDT-PTT                                          | [52]  |
|                                       | Fe-porphyring@Bis(DPA-Zn)-RGD(SOD2)-siRNA NPs | CDT-SDT                                          | [19]  |
|                                       | Hollow Fe\textsubscript{3}O\textsubscript{4} mesocrystals NPs | CDT-MHT                                          | [53]  |
|                                       | Zero-valence iron-polypyrrolidone NPs  | CDT-MHT-PTT                                      | [54]  |
|                                       | Fe-MIL-100/GOD@HA-PDA NPs             | All-in-one agent                                  | [55]  |
| Mn-based nanomaterials                | Thiol-functionalized MSN NPs@MnO\textsubscript{2} NPs | CDT                                              | [56]  |
|                                       | Bufalin@hollow MnO\textsubscript{2} NPs | CDT-chemotherapy                                 | [57]  |
|                                       | Mn-carbon dots NPs                    | CDT-PDT                                          | [58]  |
|                                       | Mn-Gd\textsubscript{2}O\textsubscript{4}@PDA NPs | CDT-PTT                                          | [59]  |
|                                       | PpIX@hollow mesoporous organosilica-MnO\textsubscript{2} RGD NPs | CDT-SDT                                          | [60]  |
|                                       | Hollow MnO\textsubscript{2}-DOX-GOD-HA NPs | All-in-one agent                                  | [61]  |
| Cu-based nanomaterials                | Cu-TCPF MOF                           | CDT                                              | [62]  |
|                                       | Hollow mesoporous silica-Cu-GOD NPs   | CDT-chemotherapy                                 | [63]  |
|                                       | Cu\textsubscript{5}Se hollow nanocubes-PEG | CDT-PTT                                          | [64]  |
|                                       | Cu-5,10,15,20-tetrabenzoatoporphyrin nMOF and anti-PDL-1 | CDT-PDT-immunotherapy                           | [65]  |
|                                       | Ce6@Cu-MOF NPs                        | CDT-SDT                                          | [66]  |
| Other metal-based nanomaterials       | TiO\textsubscript{2}-ruthenium(II) complexe NPs | CDT                                              | [67]  |
|                                       | MoS\textsubscript{2}@GOD-tirapazamine-chitosan NPs | CDT-chemotherapy                               | [68]  |
|                                       | ZIF-67-DOX@PpIX@ZIF@PDA NPs           | CDT-PDT-chemotherapy                             | [69]  |
|                                       | WO\textsubscript{3}@γ-Poly-L-glutamic acid NPs | CDT-PTT                                          | [70]  |
|                                       | TiO\textsubscript{1}+x-PEG NPs        | CDT-SDT                                          | [71]  |
|                                       | Au\textsubscript{2}Pt-Ce6-PEG NPs     | All-in-one agent                                  | [72]  |
enzyme over-expression (Ec-pE) to generate H$_2$O$_2$ at the tumor site [95]. The chemically decorated magnetic Fe$_3$O$_4$ NPs (MNP) on the surface of the engineered bacteria performed as a Fenton-like reaction catalyst to convert H$_2$O$_2$ to cytotoxic •OH. NDH-2 transferred accepted electrons to oxygen to produce H$_2$O$_2$. With the accumulation of H$_2$O$_2$, cancer cell death was induced by plenty of generated •OH (Fig. 2). This study shows that self-supplied therapeutics can be achieved without direct H$_2$O$_2$ provision.

Other metal-based nanomaterials
Manganese-based nanomaterials can release manganese ions to catalyze Fenton-like reactions, making them widely used in cancer diagnostics and therapeutics [96–98]. Owing to the enhanced spin–spin relaxation of manganese, manganese-based nanomaterials also exhibit low toxicity, tumor targeting ability, and potential magnetic resonance (MR) imaging contrast [99]. In one study, MnO$_2$-containing nanoparticles were used to deplete GSH via the reaction between MnO$_2$ and the thiol groups [56]. The Mn$^{2+}$ was released due to the reaction, which consequently triggered the Fenton-like reaction. The MnO$_2$-containing NPs were able to both deliver Fenton-like Mn$^{2+}$ and deplete intracellular GSH. Mn$^{2+}$ induced the generation of •OH from H$_2$O$_2$ via the Fenton-like reaction. Upon uptake of the NPs by cancer cells, the shell of MnO$_2$ underwent the reduction by intracellular GSH to form glutathione disulfide and Mn$^{2+}$, which enhanced CDT by GSH depletion. In another study to enhance CDT, a hybrid Fe$_5$C$_2$@MnO$_2$ NP, GOD was loaded to generate extra H$_2$O$_2$ [100]. Acidic TME not only induced the decomposition of MnO$_2$ nanoshell into Mn$^{2+}$ and O$_2$, but also triggered the release of GOD. Then, the released GOD not only effectively exhaust glucose in cancer cells, leading to starvation therapy, but also simultaneously generated plenty of H$_2$O$_2$ to accelerate the subsequent Fenton reaction to produce •OH for enhanced anticancer efficacy. As metal ions not only in the NPs but also in the metallic complex could trigger the Fenton-like reaction, in yet another study, using a Mn-Cu bimetallic complex, the Mn(II) catalyzed Fenton-like reaction to produce ROS to induce tumor cell death [101]. In addition, the copper depleted GSH to prevent ROS depletion, which further enhanced the CDT effect.

Besides manganese, copper-based nanomaterials have attracted broad attention in recent years because of their low cost, high natural abundance, and easy synthesis [102]. Particularly, copper-based nanomaterials can induce the Fenton-like reaction in wide pH range, with comparable and even better performance compared to iron-based nanomaterials [103]. It has been reported that Cu$_2$S-PEG nanodots ($\leq$ 5 nm) can produce high amounts of •OH by decomposing tumor-overexpressed H$_2$O$_2$ [104]. The generated •OH exhibited an augmented synergistic cancer therapeutic effect to the nanodots’ PDT at NIR-II wavelength range (1000–1350 nm). In another study, Gd$^{3+}$ doped CuS NPs were shown to enable MRI guidance for CDT [105]. The Cu$^{2+}$ of NPs reacted with GSH to generate Cu$^+$, which further catalyzed the Fenton-like reaction to induce tumor death. In yet another study, self-assembled copper-amino acid mercaptide NPs
(Cu-Cys NPs) were intracellularly activated by both GSH and H_2O_2, which were overexpressed in cancer cells [106]. The Cu-Cys NPs exhibited efficient CDT for drug-resistant breast cancer. The Cu-Cys NPs reacted with intracellular GSH to deplete GSH and reduce Cu^{2+} to Cu^{+}. Subsequently, Cu^{+} triggered the Fenton-like reaction to produce cytotoxic •OH. The high concentrations of GSH and H_2O_2 inside Cancer cells were key factors to trigger the intracellular redox reactions; therefore, the Cu-Cys NPs exhibited significantly higher toxicity to Cancer cells than normal cells. Apart from these studies, in one study, as GOD can be used to produce starvation therapy, it was loaded into copper-embedded hollow mesoporous silica (HMSN-Cu) NPs [63]. Once internalized in cancer cells, GOD-catalyzed starvation therapy produced gluconic acid to accelerate the Cu^{2+} release from the collapsed HMSN-Cu framework. Cu^{+}-mediated Fenton-like reaction and Cu^{2+}-induced GSH depletion was promising to synergistically strengthen starvation therapy. In a very recent study, a single-atom copper species (Cu-HNCS) was prepared and exhibited direct catalysis ability to decompose both O_2 and H_2O_2 to ROS [107]. The generated ROS oxidized intracellular biomolecules automatically, which resulted in an enhanced inhibition of tumor growth. Notably, the Fenton-like reaction showed ~5000 times turnover frequency of Cu species than that of Fe in Fe_3O_4 NPs.

Besides iron, manganese and copper, Fenton-like reactions can be catalyzed by other metal cations, such as Ti^{3+}, Ir^{3+}, Cr^{4+}, Ce^{3+}, Co^{3+}, and Mo^{3+} [108–111]. For example, a ruthenium complex (abbreviated as N3) was conjugated to a TiO_2 NP to produce TiO_2-N3 [67]. When exposing TiO_2-N3 to light, it produced three- and four-fold more cytotoxic •OH than TiO_2 intrinsically. In another example, using prepared MoSe_2/CoSe_2@PEG NPs, near infrared (NIR) light not only triggered PTT but also induced the efficient electron-hole separation to result in efficient H_2O_2 generation [111]. The generated H_2O_2 was further decomposed into •OH via the Fenton-like reaction. The system not only supplied O_2 to relieve the tumor hypoxia but also extra H_2O_2 for Fenton-like reaction. These advances demonstrate that inorganic nanomaterials can be rationally designed to manipulate therapeutic platforms based on Fenton or Fenton-like reactions for efficient antitumor therapy.

**Organic nanomaterials**

Besides inorganic nanomaterials, several organic agents, such as metal–organic framework (MOF) and ferrocene, can also be used as catalysts for Fenton-like reactions [112, 113].

With their strong catalytic ability, MOF materials have been widely studied as catalysts for Fenton-like reaction. Ultrathin two-dimensional MOF of Cu-TCPP nanosheets have been reported to be promising for Fenton-like reaction-assisted cancer therapy [62]. The NPs consisted of Cu^{2+} and tetrakis(4-carboxyphenyl) porphyrin (TCPP) ligand. The TCPP ligands are peroxidized by H_2O_2 under acidic TME, and further reduced to ROO• in the presence of peroxidase-like Cu-TCPP nanosheets and copper ions. GSH depletion by the incorporated Cu^{2+} in the nanosheets also enhanced the therapeutic efficiency.

Ferrocene is promising as a catalyst for the Fenton reaction [114]. One study explored the feasibility of using ROS-sensitive NPs (P@P/H NPs) containing ferrocene and β-cyclodextrin inclusion complex (β-CD@Fc) to prevent tumor metastasis by intracellular ROS amplification and subsequent cascade biological reaction activation [115]. PLGA-β-CD and polyethyleneimine-Fc (PEI-Fc) were conjugated with β-CD@Fc to form an ROS-responsive amphiphilic polymer (PLGA-β-CD@PEI-Fc), which was then self-assembled into NPs (P@P NPs). Finally, heparin absorbed onto P@P NPs via charge interaction and then DOX was loaded by absorption. After the P@P/H NPs were internalized by the cancer cells, they rapidly disassembled and released DOX and Fe^{2+} in the presence of H_2O_2, leading to rising •OH levels, which then destroyed the mitochondrial membrane and released cytochrome c to activate the caspase apoptosis pathway, which consequently resulted in a synergistic effect of chemotherapy and CDT.

**Fenton and Fenton-like reactions-mediated combination therapy**

Combination therapy, which integrates multiple therapeutic agents into one nanoplatform, is generally more effective than monotherapy [116, 117]. For example, Vyxeos, a FDA-approved liposomal anticancer nanomedicine that is comprised of daunorubicin and cytarabine in fixed ratio, has been shown to increase the survival time of patients [118]. Nanomedicines combining Fenton/Fenton-like reactions with other therapeutic modalities may further improve anticancer efficiency. Fenton and Fenton-like reactions-mediated combination therapy can enhance therapeutic efficiency by relieving tumor hypoxia through O_2 production or by damaging tumor cells by highly toxic ROS in situ. Therefore, multifunctional NPs for Fenton reaction-based combination therapy have increasingly been recognized as a promising strategy for tumor therapy and have been explored in combination with chemotherapy, PDT, PTT, gas therapy, sonodynamic therapy, radiotherapy, immunotherapy, and magnetic hyperthermia therapy (MHT) (Fig. 3).
Combination of Fenton and Fenton-like reactions with chemotherapy

Chemotherapy is one of the main strategies to treat cancer. Various chemotherapy drugs, such as doxorubicin (DOX), cisplatin (CDDP), camptothecin (CPT), and tirapazamine (TPZ), have clear therapeutic mechanisms and can have remarkable therapeutic effects. However, drug resistance may develop and toxicity remains a limiting factor for chemotherapy. Recently, Fenton reaction/chemotherapy combination therapy have been demonstrated to strengthen the therapeutic efficiency of chemotherapeutic drugs with reduced side effects, even against drug-resistant cancer cells [119–121].

To enhance the therapeutic effect of loaded DOX, Fe$^{3+}$ and Mn$^{2+}$ have been incorporated into NPs to enable Fenton and Fenton-like reactions to generate ROS [122–124]. DOX and platinum prodrugs have also been encapsulated in Fe$^{3+}$-polyphenol networks NPs [50], whereby the Fe$^{3+}$-mediated Fenton reaction induced the generation of highly toxic •OH to synergize with chemotherapy. In one study, as a H$_2$O$_2$ inducer, β-lapachone was loaded into a pH/ROS dual-responsive NP, which consisted of pH-responsive polymer and ROS-responsive polyprodrug [125]. The NPs disassembled when triggered by low pH, and then released β-lapachone and polyprodrug. The β-lapachone supplied endogenous H$_2$O$_2$ for the Fenton reaction, which produced ROS to trigger DOX release, allowing combination therapy consisting of CDT and chemotherapy to take place. In another study, a ferroptosis-inducing agent was fabricated based on arginine-rich manganese silicate nanobubbles (AMSNs), which can deplete GSH efficiently and induce ferroptosis by GPX4 inactivation [126]. In addition, DOX was loaded to the surface of AMSNs to perform chemotherapy, achieving a synergistic effect of CDT and chemotherapy.

It was found that platinum (Pt) can act as ROS inducer [127]. Thus, several studies have used platinum to enhance combination therapy consisting of Fenton and Fenton-like reactions with cisplatin chemodrugs. For example, Fe$_3$O$_4$@PEI-Pt(IV)-PEG NPs were fabricated to enhance cisplatin-based chemotherapy by iron-mediated Fenton reaction [128]. Cisplatin activated the formation of superoxide radical (O$_2^-$) and H$_2$O$_2$ from O$_2$, while iron-catalyzed Fenton chemistry converted H$_2$O$_2$ into •OH, leading to lipid and protein oxidation and DNA damage. In another study, organic theranostic nanomedicine (PTCG NPs) were incorporated with the platinum(IV) prodrug (Pt-OH) Fe$^{3+}$ [129]. The activated cisplatin elevated the H$_2$O$_2$ level, which was catalyzed by Fe$^{3+}$ to produce cytotoxic ROS, thus enhancing the therapeutic efficacy. Apart from platinum, ferrocene has been used, whereby a ferrocene-containing nanovesicle (FcNV) was loaded with GOD and cisplatin (Pt) to combat multidrug-resistant tumors [130]. In the system, H$_2$O$_2$ generation was activated by Pt to enhance chemotherapy; glucose was consumed by GOD to generate H$_2$O$_2$ and gluconic acid for starvation therapy; and all H$_2$O$_2$ were catalyzed by Fenton reaction to generate cytotoxic •OH for CDT. Lastly, Mn$^{2+}$ is also promising for combination therapy, as shown in a study where the cisplatin prodrug was anchored onto the surface of MnO$_2$-coated upconversion hybrid nanocomposite, the MnO$_2$ shell was degraded by intracellular GSH, and then, the released Mn$^{2+}$ performed Fenton-like reaction for CDT to synergize with Pt-based chemotherapy [131].

H$_2$O$_2$ performs an important role in the Fenton and Fenton-like reactions-mediated CDT; thus, extra H$_2$O$_2$ induced by nanomaterials is promising to enhance the cancer therapeutic effect of CPT chemodrugs. Therefore, in one study, the H$_2$O$_2$ inducer, β-lapachone, and camptothecin prodrug were co-loaded into iron oxide NPs [132]. The H$_2$O$_2$ that was induced by β-lapachone reacted with iron ions via the Fenton reaction to produce cytotoxic •OH for CDT as well as activate the release of CPT for chemotherapy. In the hybrid FeMOF NPs with Au NPs anchored on the surface and CPT loaded inside, the NPs converted glucose into H$_2$O$_2$ for TCPP(Fe)-mediated Fenton reaction, enhancing CDT-catalyzed chemotherapy [133]. In another study, the hybrid NPs, Fe/G@R-NRs, were prepared by loading responsive polyprodrug polymersomes with ultrasmall iron oxide NPs and GOD (Fig. 4) [134]. Triggered by the acidic TME, Fe/G@R-NRs released GOD to catalyze starvation therapy, and Fe to catalyze the Fenton reaction, which generated •OH to react with polyprodrug polymersomes to release CPT for chemotherapy.

Many other common chemotherapeutic drugs have also been explored for synergistic treatment with Fenton and Fenton-like reactions. Tirapazamine (TPZ) exhibits selective cytotoxicity for hypoxic solid tumors. Thus, in
several studies, TPZ has been explored for its potential use in the Fenton reaction system, whereby oxygen was depleted and TPZ was activated [135, 136]. Furthermore, the GSH synthesis inhibitor, L-buthionine sulfoximine (BSO), has been explored to synergize with the Fenton reaction to deplete intracellular GSH, showing that this enhanced the chemotherapy and radiotherapy [137]. Mitomycin c has also been explored to synergize with the Fenton reaction by being encapsulated into superparamagnetic iron oxide NPs@PEG (SPIONs@PEG) [138]. The surface-anchored GOD catalyzed and converted glucose into gluconic acid and H$_2$O$_2$ for the Fenton reaction to strengthen chemotherapy. In addition, parthenolide, chloroquine, cinnamaldehyde, and bufalin have been explored as chemotherapeutic drugs to synergize with Fenton reaction-mediated CDT for an enhanced therapeutic effect [57, 139, 140].

**Combination of Fenton and Fenton-like reactions with PDT**

PDT has been used for the management of neoplastic and nonmalignant diseases and is attracting more and more attention in recent years [141]. PDT is composed...
of three components: photosensitizers (PSs), light source, and oxygen. PSs can generate ROS under light irradiation, leading to the selective killing of tumors and cancer cells. According to the skeleton structure of their molecules, PSs are mainly divided into porphyrins, chlorins, and phthalocyanines. However, PDT has been limited by several unresolved challenges, such as inefficient therapeutic efficiency as a result of the hypoxic TME [142]. Recently, the combination of Fenton and Fenton-like reactions with PDT has been demonstrated to enhance the therapeutic antitumor effect [143, 144].

With their high ROS generation efficiency, good light stability, and low dark toxicity, porphyrins are often used as molecular probes and PSs, showing high cytotoxicity towards cancer cells under light irradiation [145]. To achieve targeted delivery to the tumor, the photosensitizer Zinc(II) protoporphyrin IX (ZnP) was inserted into the iron storage protein bacterioferritin (Bfr) in one study [146]. The inner cavity was loaded with a ferric oxyhydroxide polymer and then conjugated with polyethylene glycol on the outer surface. Under light irradiation, 3ZnP in the Bfr protein shell reduced Fe3+ in the enclosed [FeO(OH)]n core to Fe2+, which subsequently triggered the Fenton reaction to generate ROS for PDT enhancement. In another study, in order to enhance the tumor accumulation of the nanomaterial, the targeted molecule AS1411 aptamer was modified onto porphyrin tumor accumulation of the nanomaterial, the targeted molecule AS1411 aptamer was modified onto porphyrin.
GSH, which yielded Fe$^{2+}$ for the Fenton reaction to take place, enhancing PDT.

**Combination of Fenton and Fenton-like reactions with PTT**

PTT is a type of therapy that relies on light irradiation to generate a local temperature elevation for cancer ablation [159]. The combination of Fenton and Fenton-like reactions with PTT has exhibited improved therapeutic efficiency over monotherapy [160]. Both inorganic materials and organic materials can be used as photothermal materials. Inorganic materials mainly include the noble metals (e.g., Au, Ag, and Pt), metal chalcogenides (e.g., CuS), and carbon-based nanomaterials [161, 162]. Organic photothermal materials mainly include small molecule dyes (e.g., indocyanine green, prussian blue) and conjugated polymers (e.g., polyaniline, polypyrrole, polythiophene, polydopamine) [163–165]. One main issue for PTT is that insufficient light penetration depth may lead to incomplete elimination of tumor cells, and residual tumor cells may lead to tumor recurrence and distant metastasis. The combination of PTT and Fenton/Fenton-like reactions has demonstrated great potential to achieve synergistic effects and improve therapeutic performance [166]. On the one hand, ROS production can be promoted under a higher temperature by light-enhanced Fenton reaction. On the other hand, ROS production can enhance PTT effect by sensitizing tumor cells [167].

Noble metals exhibit a strong resistance to oxidation and are regarded the most classical photothermal materials [72, 168]. Noble metals absorb light energy and then release energy in the form of heat via non-radiative decay. In addition, many metal ions released from the noble metal nanomaterials are efficient catalysts for Fenton/Fenton-like reactions [169]. In one study, Cu$_2$Mo$_4$S$_4$/Au NPs were prepared by depositing plasmonic Au NPs into Cu$_2$Mo$_4$S$_4$ nanosheets [170]. The prepared Cu$_2$Mo$_4$S$_4$/Au NPs exhibited excellent photothermal conversion property and ROS generation capability, enabling synergistic therapy of PTT and PDT. Moreover, the Cu$_2$Mo$_4$S$_4$/Au NPs converted H$_2$O$_2$ into O$_2$ via the Fenton-like reaction to relieve tumor hypoxia and to enhance the therapeutic effect. In another study, hybrid NPs were prepared by coating upconverting NPs with iron-porphyrin MOFs on the surface and integrating Au NPs [171]. The NPs tuned the visible light harvesting ability of MOFs to excite MOFs for PDT. Moreover, the Au NPs depleted glucose and produced large amount of H$_2$O$_2$, resulting in enhanced Fenton reaction catalyzed by Fe$^{2+}$ of MOFs. In yet another study, the nanozyme made of PtFe@Fe$_3$O$_4$ exhibited dual enzyme-like activities of both intrinsic peroxidase-like and catalase-like activities in the acidic TME [52]. On the one hand, the prepared nanozyme promoted ROS production by direct electron transfer and Fe$^{3+}$-mediated Fenton reaction. On the other hand, ROS generation was significantly improved by the
photothermal effect of nanozymes, achieving the synergistic catalytic therapy and PTT. In one last study, DOX@Fe(III)@WS2-PVP NPs were designed by loading Fe(III)@WS2-PVP fabricated via one-pot synthesis process with DOX [172]. On the one hand, the redox reaction between Fe²⁺ and WS₂ generated Fe³⁺ and WO₃²⁻. On the other hand, Fe³⁺ catalyzed the Fenton reaction which generated Fe²⁺ for the redox reaction. This repetitive endogenous redox reaction resulted in biodegradation and DOX release from DOX@Fe(III)@WS₂-PVP, leading to chemotherapy and CDT for PTT enhancement.

With their wide range of optical absorption and reasonable photothermal properties, metal chalcogenides have received great attention in recent years [173–175]. Their use has been explored to achieve synergistic combination therapy of Fenton-like activity and PTT [176, 177]. For example, in one study, (Cu₂-,Se)-Au Janus NPs were prepared for tri-combination antitumor therapy [178]. In the designed NPs, both the Cu₂-,Se and the Au promoted •OH generation. In addition, the Janus structure promoted photo-induced electron–hole separation to produce additional •OH. Both Cu₂-,Se and Au contributed to PTT and promoted the reactions. As a result, synergistic tri-combination antitumor therapy was achieved. In another study, ultrasmall chalcopyrite CuFeS₂ NPs were prepared by using bovine serum albumin (BSA) as a template [179]. The prepared NPs possessed pH-independent Cu-catalyzed Fenton-like reaction property to produce •OH for enhanced PTT. BSA was used to anchor Cu and Fe ions based on the excellent affinity of carboxyl groups and the surfactant. In yet another study, CuS NPs, another kind of NIR absorbing material for PTT was used, whereby the Cu²⁺ released from the NP was found capable to trigger the Fenton-like reaction [180]. When CuS NPs were integrated with iron-containing prodrug, the hybrid NPs not only acted as a PTT agent for photothermal ablation of tumor cells but also acted a catalyst to catalyze the regeneration of high-active Fe²⁺ from low-active Fe³⁺, enhancing Fe²⁺-mediated Fenton reaction. In another application of CuS NPs, they were integrated with MnO₂ to generate the hybrid HMCMD NPs [181]. The HMCMD NPs possessed excellent photothermal conversion efficiency and the release of the loaded DOX was promoted under laser irradiation to enhance DOX-mediated chemotherapy. Meanwhile, Mn²⁺ released from the HMCMD NPs through a redox reaction between MnO₂ and intracellular GSH promoted the decomposition of intracellular H₂O₂ by the Fenton-like reaction to generate highly toxic •OH for synergistic chemotherapy/CDT/PDT. Lastly, one study prepared CoS₂ NPs via the self-assembly of CoS₂ nanoclusters [182]. Co₂⁺-mediated Fenton-like reaction enhanced the CoS₂ mediated-PTT.

Carbon-based materials, such as carbon nanotubes, graphene, graphene oxide, and carbon dots, can also convert light energy to heat energy for cancer treatment [183]. Therefore, in one study, the hollow carbon matrix core, which contained ultrasmall Fe₃O₄ NPs, was coated with a nanoflower-like MnO₂ shell to form a redox and light-responsive nanoplateform [184]. Fe²⁺ and Fe³⁺ released in the acidic TME catalyzed the Fenton reaction for enhanced PTT. In another study, hollow porous carbon was used to coat FeS₂ (HPFeS₂@C) NPs which were further loaded with tannic acid (TA) and GOD [185]. After endocytosis by cancer cells, GOD effectively catalyzed glucose to generate H₂O₂, which led to the generation of highly toxic •OH via Fe²⁺-mediated Fenton reaction. Meanwhile, TA reduced the generated Fe³⁺ back to Fe²⁺ to recycle the Fenton reaction for enhanced therapeutic effect.

Prussian blue is an inorganic material that contains a ferrous element and that possesses good absorption at the NIR wavelength region. Prussian blue-based nanomaterials have shown promise for both PTT and Fenton-reaction mediated CDT [186]. In one study, MIL-100 (Fe) coated K₂Mn[Fe(CN)₆] NPs (PBAM) were prepared for CDT and PTT combination therapy [187]. In the mildly acidic TME, the MIL-100 shell was degraded to release Fe³⁺, which further exchanged with Mn²⁺ to synthesize Prussian blue for PTT. Additionally, Mn²⁺ catalyzed the Fenton-like reaction, enhancing PTT. The in vitro data confirmed that the T₁-weighted MRI with Mn²⁺ contrast and photoacoustic imaging with Prussian blue contrast obtained more detailed and precise tumor information for cancer therapy. The in vivo data further exhibited that the combination of Mn²⁺-mediated CDT and Prussian blue-mediated PDT achieved synergistic anticancer performance under the guidance of PA/MRI. And with their high tumor specificity, PBAM showed promise to monitor invisible lymph node metastases and to have an accurate theranostic effect.

Ferrous-sulfur NPs are a class of nanomaterials possessing strong absorbance in the NIR wavelength region, making them a good PTT agent to combine with ferrous ion-mediated Fenton reaction [188]. In one study, defect-rich Fe₅S₄ tetragonal nanosheets (TNSs) were fabricated by a hot-injection thermal decomposition reaction and then modified with a PVP coating [189]. PVP-coated Fe₅S₄ TNSs produced localized heat by PTT from the defect-rich structure, which enhanced the Fenton process by utilizing the excess H₂O₂ in the TME. In return, the produced •OH inhibited tumor growth and recurrence after PPT, achieving synergetic therapy of Fenton reaction and PTT. In another study, FeS₂@C-ICG-PEG NPs were prepared by loading indocyanine green (ICG) into the FeS₂@C yolk-shell and modifying PEG on the
C yolk-shell surface [190]. FeS2@C-ICG-PEG possessed high photothermal conversion efficiency, enabling enhanced PTT. Besides, FeS2@C-ICG-PEG possessed NIR-triggered ROS (•OH and O2–) and oxidized water to form O2 under NIR irradiation to relieved tumor hypoxia. Moreover, FeS2-mediated Fenton reaction and ICG-mediated PTT enhanced the therapeutic effect. In yet another study, thermally oxidized pyrite nanosheets (TOPY-PEG NSs) were modified on the surface [191]. The TOPY-PEG NSs catalyzed PDT via electron transfer between their FeS2 core and Fe3O4 shell. In addition, the Fe2O3 shell and Fe3+ depleted GSH and generated Fe2+ for the Fenton reaction, enhancing not only PDT but TOPY-PEG NSs-mediated PTT. And the fluorescent, photothermal imaging and photoacoustic capabilities of the TOPY-PEG NSs were shown to allow multimodal imaging-guided cancer treatment. In one last study, except for Ferrous-sulfur NPs, ferrous phosphate nanorods (Fe3P NRs) were shown to be a superior PTT agent as well as CDT agent by Fe3+‐mediated Fenton reaction [192].

Among organic nanoplatforms, conjugated polymers with excellent optical properties have gained tremendous popularity recently. The large π-conjugated backbone and high electron delocalization structure of conjugated polymers have excellent light amplification and light harvesting properties, thus providing new opportunities in the fields of bioimaging and phototherapy [193, 194]. Polydopamine (PDA) is a kind of conjugated polymer with excellent absorption in the NIR wavelength region, which facilitates its application for PTT [195]. Thus, metal ions could be incorporated into the PDA-based NPs to enhance PDA-mediated PTT via Fenton or Fenton-like reaction-mediated CDT [196]. In order to further improve the synergistic effect of PDA-based PTT/CDT, GOD has been incorporated into the NPs to deplete glucose and supplied H2O2 for the Fenton reaction [197]. DOX has also been further loaded into such system to explore the synergistic effect of PTT/CDT/chemotherapy [198].

Combination of Fenton reaction and sonodynamic therapy (SDT)

SDT is a cancer therapy modality triggered by low-intensity ultrasound and has emerged as a promising cancer treatment modality due to its deep penetration and non-invasive therapeutic features [199]. SDT has many advantages, including deep tissue penetration, controllability, and good patient compliance; however, its therapeutic effect is limited in the hypoxic TME and where there is low ROS release and low sensitivity [200–202]. Therefore, combining Fenton reaction with SDT can strengthen the therapeutic efficiency of either Fenton reaction or SDT [203].

Sonosensitizers like porphyrin derivatives are generally used to enhance the SDT [204]. In one study, the Fe(III)-porphyrin-based nano-sonosensitizer was fabricated by coordinating meso-tetrakis (4-sulfonatophenyl) porphyrin (TPPS) and Fe3+ as a core, and then anchoring with Bis(DPA-Zn)-RGD and manganese superoxide dismutase (SOD2) siRNA [205]. Fe3+ in the nano-sonosensitizer reduced into Fe2+ to deplete GSH and catalyze CDT for TPPS-SDT enhancement. In another study, another multifunctional nanosonosensitizer (PplIX@HMONs-MnOx-RGD, designated as PMR) was prepared by integrating a MnOx component with hollow mesoporous organosilica NPs (HMONs), protoporphyrin (PplIX) and cyclic arginine-glycine-aspartic pentapeptide [60]. These multifunctional nanosonosensitizers enhanced ultrasound-triggered SDT by improving the tumor oxygen level. The MnOx in the nanosonosensitizer acted as a nanoenzyme to convert TME overexpressed H2O2 into oxygen to facilitate SDT-triggered ROS generation and to enhance SDT efficacy. There are also some reports about the use of inorganic NPs as sonosensitizers to combine with Fenton reaction. For example, Janus Au-MnO NPs were prepared by the self-assembly of Janus Au-MnO NPs with hydrophilic thiolated PEG (PEG-SH) and hydrophobic ROS-sensitive poly-(1,4-phenyleneacetone dimethylene thioketal) (PPADT-SH) [206]. Upon ultrasound stimulation, the prepared NPs firstly disassembled into small Janus Au-MnO NPs, and then divided into Au NPs and Mn2+ ions. Mn2+‐mediated Fenton-like reaction enhanced Au-mediated SDT. In another study, PtCu3 nanocages were synthesized via one-pot solvothermal method, and then coated with PEG [207]. PtCu3-PEG nanocages acted not only a sonosensitizer under ultrasound irradiation but also a catalyst for Fenton-like reaction. Besides, the copper ion of the PtCu3-PEG nanocages depleted GSH, strengthening the combination therapy. In yet another study using titanium oxide NPs, the introduction of the iron element enhanced both SDT and CDT and resulted in synergistic combination therapy [208].

Combination of Fenton reaction and immunotherapy

Cancer immunotherapy has recently gained considerable attention as a novel therapeutic option; moreover, the rational combination of immunotherapy with other therapeutic modalities presents an appealing approach to improve cancer therapy [209–212]. In recent studies, Fenton reaction-based CDT-immunotherapy not only achieved the shrinkage of in situ tumor but effectively eradicated distant tumors [213].
The Fenton reaction can be used to modulate cellular metabolic processes for antitumor activities, e.g., hijacking the estrogen metabolic pathway [214]. High serum levels of estrogens, especially estradiol (E2), are associated with increased cancer risks. Estrogens were found to form stable adducts with DNA by generating ROS in the downstream metabolic processes in the presence of Cu$^{2+}$ mediated Fenton-like reaction (Fig. 6). The intratumoral administration of free Cu$^{2+}$ can potentially hijack the estrogen metabolic pathway and trigger cytotoxic ROS generation to reduce cell-proliferation-induced tumorigenesis and enhance effective radical therapy.

It is well known that radiotherapy (RT) can trigger the immune response but its anticancer efficacy has been limited by inadequate T cell infiltration. Thus, porous Hf-based nMOFs have been explored as effective radioenhancer [65]. The combination of nMOF-mediated low-dose RT with the anti-programmed death-ligand 1 (anti-PD-L1) antibody exhibited effective therapeutic effects to distant tumors via abscopal effects. When copper was doped into hybrid NPs, the resultant product exhibited synergistic PTT, PDT, CDT as well as activated immune responses effectively [215]. Further combination with anti-PD-L1 checkpoint blockade therapy resulted in successful suppression of distant tumor growth and cancer metastasis.

It is also well known that the TGF-β inhibitor can regulate the TME to induce macrophage polarization from M2 to M1, which can regenerate H$_2$O$_2$. Thus, the TGF-β inhibitor has been loaded into the PEGylated iron manganese silicate NPs (IMSN) to trigger the synergistic cancer therapy [216]. The IMSN exhibited both peroxidase-like and catalase-like activities in the acidic TME, thus generating •OH and O$_2$, respectively. The generated H$_2$O$_2$ induced by TGF-β inhibitor was an efficient supplement to the TME for IMSN-based combination therapy.

Fig. 6 a Hormone-induced Cu-mediated ROS generation process. b Synergy of checkpoint blockade immunotherapy and nMOF-mediated radical therapy triggered by both hormone and light stimulation. Reproduced with permission from Ref. [214]
Combination of Fenton reaction and magnetic hyperthermia therapy (MHT)

MHT is a strategy using an external alternating magnetic field to induce the relaxation and hysteresis loss of magnetic NPs, resulting in magnetic-heat conversion for cancer therapy [98]. MHT can treat tumors by producing localized heat with minimum adverse effects and without depth limitations [217]. The combination of the Fenton reaction and MHT is promising to produce more effective treatment with less side effects [54].

Hollow Fe₃O₄ mesocrystals have been shown to enhance Fe₃O₄-mediated MHT by the Fenton reaction [53]. On the one hand, the Fenton reaction produced •OH which induced cell apoptosis and reduced the expression of heat shock proteins, enabling low-temperature-mediated magnetic hyperthermia. On the other hand, in situ hyperthermia in turn facilitated the Fenton reaction to achieve synergistic combination therapy. In another study, the lipophilic iridium(III) cation in the Ir(III) complexes modified MnFe₂O₄ NPs acted as a target ligand to the tumor [218]. On exposure to an alternating magnetic field, the MnFe₂O₄@Ir NPs caused localized hyperthermia, leading to mitochondrial damage and even cell death. Moreover, Fe³⁺ on the surface of NPs converted into Fe²⁺ by reacting with GSH, catalyzing the Fenton reaction to enhance magnetic hyperthermia. In yet another study, the further loading of GOD not only resulted in starvation therapy but also generated more H₂O₂ at the tumor, resulting in synergistic starvation-chemodynamic-hyperthermia tumor therapy [219]. Lastly, one study showed that in graphene oxide-grafted magnetic manorings, the elaboration of ferrimagnetic vortex-domain iron oxide nanoring and graphene oxide exhibited efficient thermal conversion and amplified the Fenton reaction-induced ROS level significantly under an alternating magnetic field [220]. The magnetothermal effect and ROS generation activated the in vivo immunologic effect to carry out efficient MHT in vivo.

Combination of Fenton reaction and RT

RT is a widely used cancer therapeutic modality in clinic. Tumor hypoxia is a major reason for RT resistance. As Fenton and Fenton-like reactions can produce O₂₂ to relieve tumor hypoxia, they are promising to enhance RT [221]. Traditionally, the therapeutic efficacy of RT is a result of direct radiation damage and indirect damage caused by •OH. In one study, Janus-like Au-Fe₂C NPs that performed as Fenton reaction catalysts were synthesized to sensitize RT by generating more hydroxyl radicals (•OH) than that by pure Au NPs under radiation [222]. The catalysis-based radiosensitization strategy exhibited improved anticancer performances both in vitro and in vivo.

To further improve the sensitization effect by the Fenton reaction, in another study, Hafnium-based nanoscale metal—organic frameworks (Hf-nMOFs) with uniformly dispersed Fe³⁺ were constructed [223]. The NPs generated tremendous ROS, resulting in persistent ROS stress and reassorted cell cycle distribution. In addition, high-energy electrons resulting from Hf⁴⁺ partially converted H₂O to •OH and relaxed to a low-energy state to facilitate the reduction of Fe³⁺ to Fe²⁺ that promoted the production of •OH via the Fenton reaction. The NPs exhibited improved radiotherapeutic effects on tumors by both the Fe²⁺-based Fenton reaction and Hf⁴⁺-induced X-ray energy conversion. In yet another study, the incorporation of anti-PD-L1 improved the local therapeutic effect of RT to distant tumors [65].

To improve the selectivity and controllability of the combination therapy of Fenton-like reaction and RT, a TME-responsive Cu₃(OH)PO₄ NP was synthesized [224]. The Cu₃(OH)PO₄ NP was responsive to both H₂O₂ and X-ray. Under X-ray irradiation, the NP generated Cul sites to serve as a Fenton-like catalyst to decompose over-expressed TME H₂O₂ into cytotoxic •OH. Meanwhile, the Fenton-like reaction was limited within normal tissues and organs due to lower H₂O₂ level compared to that at the tumor. This TME responsive Fenton-like catalyst ensured the radiosentization in hypoxic tumors but not in normal cells.

Combination of Fenton reaction and gas therapy

It is well known that some gases perform as signal molecules in vivo that influence many pathophysiological processes such as cancer. Therefore, controllable gas release and tumor-targeted gas delivery is highly desired to avoid the risk of poisoning normal tissues and organs, and to amplify their cancer therapeutic effect [225].

In a study using Fe₁−ₓS NPs, the increased temperature induced by NIR light irradiation prompted Fenton reaction-mediated •OH generation [226]. In addition, these NPs produced H₂S gas in the acidic (pH = 6.5) TME, which suppressed the enzyme activity of cytochrome c oxidase to inhibit the tumor growth. Both in vitro and in vivo results demonstrated that the H₂S-mediated gas therapy and Fenton reaction-mediated CDT produced a synergistically enhanced antitumor performance, thereby opening up a new method for gas-mediated cancer treatment. In another study, the released H₂S gas produced extra suppression on the intracellular catalase activity of cancer cells to induce the accumulation of H₂O₂ that facilitated Fenton reaction-mediated ROS generation [227].

Nitric oxide (NO) is another signal molecule exhibiting multiple antitumor activities [228]. Therefore, one study incorporated a GSH-sensitive NO donor into the
iron-based nanoscale coordination polymer (NCP) [229]. The high level of GSH in tumor cells triggered the specific release of NO in situ. Meanwhile, Fe$^{2+}$-mediated Fenton reaction at the tumor generate cytotoxic •OH for CDT. In addition, the Haber–Weiss reaction between Fe$^{2+}$ with H$_2$O$_2$ produced plenty of •O$_2^-$, which further reacted with NO to generate ONOO$^-$, which was more cytotoxic than •O$_2^-$ or NO.

Though carbon monoxide (CO) poisoning is harmful to human life, the controllable release and tumor targeted delivery are allow its use as an antitumor agent. In one study, in order to apply metal carbonyl complexes in an antitumor agent, the iron pentacarbonyl (Fe(CO)$_5$) was incorporated inside an Au nanocage under an oxygen-free atmosphere [230]. The Fe(CO)$_5$ formed an iron oxide shell on the nanocage surface under aerobic conditions to avoid the leakage and oxidation of the caged Fe(CO)$_5$. The resulting NPs could be activated under NIR light irradiation to generate CO and iron ions, triggering CO-mediated gas therapy and iron ion-mediated CDT. The generated CO and iron ions exhibited excellent synergistically enhanced antitumor effects.

Diagnosis and monitoring of cancer therapy
Cancer theranostics, an approach that integrates diagnosis and treatment, has been a hot research topic of late [231]. Various imaging modalities can be combined with various therapies to form tumor-targeted multifunctional nanoprobes that aim at improving the identification of malignant tumors while also having a significant treatment effect [232].

In addition to inducing the death of tumor cells, Fenton and Fenton-like reactions be applied for diagnosing cancer and monitoring treatment response to guide therapies. Towards this end, various Fenton and Fenton-like-based nanosensors have been adapted for use with different imaging modalities including magnetic resonance imaging (MRI), computed tomography (CT), and photoacoustic imaging (PAI) (Fig. 7) [233, 234].

MRI-guided cancer theranostics
Owing to its superior sensitivity, high spatial resolution, and non-invasive and radiation-free characteristics, MRI has been widely used in clinical diagnosis [235]. In MRI, the atomic nuclear magnetization signal is reconstructed and converted into two-/three-dimensional images which are used for monitoring in vivo therapeutic performance [236]. To improve signal enhancement at the tumor site, TME-responsive NPs are beneficial [237].

The combination of MRI and cancer therapy has been demonstrated as an effective theranostic strategy. Recently, tumor-responsive PEGylated antiferromagnetic pyrite (FeS$_2$) NPs were developed to generate an enhanced MRI signal [238]. The FeS$_2$-PEG NPs promoted the Fenton reaction after entering the tumor cells, which not only led to the production of toxic ROS but also allowed H$_2$O$_2$ content in the tumor area to be monitored via T1 and T2 signal enhancement, thus enabling MRI monitoring of therapeutic performance. In addition, the localized heat generated by FeS$_2$-PEG NPs accelerated the intratumoral Fenton reactivity and achieved a synergetic PTT/CDT effect. This MRI-guided synergetic nanoplatform opens up a new direction for anticancer theranostics.

In another study, to enhance the sensitivity of MRI, switchable MRI-guided core–shell-structured Fe$_5$C$_2$@Fe$_3$O$_4$ NPs with a Fe$_5$C$_2$ core and a Fe$_3$O$_4$ shell were fabricated [239]. Compared with Fe$_3$O$_4$ NPs, the Fe$_5$C$_2$@Fe$_3$O$_4$ NPs exhibited high magnetization and discharged ferrous ions more effectively in acidic TME. The high magnetic
property of Fe₃C₆@Fe₂O₄ NPs benefited the visualization of tumor aggregation via T2-weighted MRI and magnetic targeting. Both in vitro and in vivo studies demonstrated effective ROS generation and tumor orientation, exhibiting enhanced therapeutic efficacy and low toxicity. Besides, the ionization of Fe₃C₆@Fe₂O₄ NPs in the acidic TME reduced the T2 signal, while the ferrous ions release increased the T1 signal in MRI, which provided enhanced MRI-guided cancer therapy for tumor treatment. The Fe₃C₆@Fe₂O₄ NPs provided an effective strategy for specific cancer therapy guided further by MRI.

To overcome the biological barriers of drug delivery, in one study, a precise tumor-targeting nanozyme (Ag₅S@Fe₃C-DSPE-PEG-iRGD) was rationally prepared for enhanced cancer therapy [240]. This nanozyme displayed efficient intracellular uptake, intense fluorescence, and high level of ROS production in cancer cells. Moreover, this nanozyme realized high-resolution tumor monitoring in tumor-bearing mice, including superior fluorescence imaging in NIR-II and high-sensitivity MRI, which was beneficial for tumor vascular normalization. Besides, the antitumor effect of Ag₅S@Fe₃C-DSPE-PEG-iRGD was enhanced in vivo when combined with bevacizumab-induced tumor vascular normalization. In addition, a high-degree of Ag₅S@Fe₃C-DSPE-PEG-iRGD (~90%) could be rapidly excreted from the mice within 14 days, promoting the clinical application of the nanozyme. Hence, the combination of tumor vascular normalization and imaging-guided nanozymes may accelerate the development and clinical applications of nanomedicines.

CT-guided cancer theranostics
Owing to its high efficiency and high resolution as well as its low cost, CT has been a widely used non-invasive clinical imaging technique [241]. Although CT exhibits a much higher resolution than several other imaging strategies, it remains difficult to distinguish small changes in tissue over time. In order to enhance the accuracy of disease diagnosis, various CT contrast agents have been designed and developed. The commonly used CT contrast agents in clinic are small molecule iodides; however, the toxicity and short circulation time limit their further application [242]. The development of nanosized contrast agents can effectively improve the diagnostic efficacy and reduce the side effects of contrast agents. Besides iodine-containing NPs, some heavy metal-based NPs (gold, bismuth, tantalum and lanthanide, etc.) are promising as CT contrast agents, exhibiting obvious advantages for the visualization imaging of blood vessels and tumors [243].

Because of their high-Z atoms, Au NPs with good biocompatibility and simple synthesis strategy are widely used as a contract agent to enhance CT imaging [244]. To develop a versatile nanoplatform for tumor theranostics, in one study, a novel Au@Prussian blue (Au@PB) nanocubes (NCs) was constructed via the templates method, and then DOX was subsequently encapsulated into the Au@PB NCs [245]. The in vitro and in vivo experiments demonstrated that the DOX-Au@PB NCs exhibited synergistic effects on tumor growth inhibition. Besides, owing to the excellent X-ray attenuation coefficient of Au, the Au@PB NCs displayed higher CT imaging efficiency (~27.13 HU·mL⁻¹·mg⁻¹) than the reported CT agents. This study provides a potential strategy for CT-guided tumor therapy.

In another study, a nanocomposite (Fe₃O₄@PDA@BSA-Bi₂S₃) that was composed of Fe₃O₄, polydopamine, bovine serum albumin and Bi₂S₃ was designed for MRI/CT monitored CDT/PTT combination therapy [173]. In this formulation, the stability and biocompatibility of the NPs were rendered by BSA coating. Meanwhile, the Fe₃O₄ NPs not only triggered Fenton reactions and produced highly cytotoxic •OH for tumor therapy, but also acted as the MRI contrast agent for precise cancer diagnosis. Besides, the Bi₂S₃ component exhibited outstanding photothermal transducing ability and CT imaging capacity. Besides, the high T2-relaxation time of Fe₃O₄ improved the MRI contrast, while the high X-ray attenuation coefficient of Bi enhanced the CT contrast, thereby facilitating the precise monitoring and synergistic tumor therapy. This work displays a feasible strategy to construct a composite nanoplatform for tumor theranostics.

PAI-guided cancer theranostics
Owing to its outstanding fine spatial resolution and deep tissue penetration, PAI is a promising imaging modality in clinical cancer diagnosis [246]. In PAI, the pulsed laser radiation energy is absorbed by the contrast agent and converted into an acoustic signal, and then the signal is measured and images are constructed by a scanning transducer [247]. The development of nanomaterials as PAI contrast agents with high sensitivities and optimal NIR absorption is crucial to PAI applications.

By decorating the 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) on the surface of graphene quantum dot nanozyme (GQDzyme) and then camouflaging with FA conjugated natural erythrocyte membranes, a novel exosome-like GQDzyme/ABTS vesicle was developed as an in vivo H₂O₂-sensitive PAI agent in the treatment of nasopharyngeal carcinoma in one study [248]. In the presence of H₂O₂, ABTS was effectively oxidized by the peroxidase-like activity of GQDzyme. The achieved oxidized ABTS displayed strong NIR absorbance, and the GQDzyme/ABTS NP showed to be a promising catalytic PAI contrast agent with high sensitivitivy to H₂O₂ in the cancer cells. Attractively, the lysosomal escape of the nanozyme vesicles promoted their
interactions with H₂O₂ in cancer cells. Due to the photothermal properties and optical absorption of ABTS, PA signal was selectively triggered in the cancer cells with overexpressed H₂O₂ based on the peroxidase-like activity of GQDzyme. In addition, GQDzyme acted as nanocarriers for delivery and tracking drugs, exhibiting optimal stealth ability and biocompatibility for long blood circulation time. Overall, the GQDzyme/ABTS-based nanozyme vesicle was shown to be a promising PAI contrast agent for non-invasive tumor imaging.

In another study, to effectively exterminate tumors, biocompatible ferrous phosphide nanorods (FP NRs) was constructed under the NIR-II laser illumination, exhibiting high photothermal conversion efficiency [249]. Owing to their excellent photothermal conversion efficiency (56.6%) and traverse relaxivity (277.79 mm² s⁻¹), the FP NRs acted as optimal PAI and MRI agents, achieving dual-mode imaging guided enhanced combination therapeutic efficacy of CDT and PTT. The in vitro and in vivo experiments exhibited that the FR NRs could efficiently induce the death of cancer cells and completely exterminate tumor. The metallic phosphide-based NRs could realize deep tissue penetration under NIR-II laser irradiation and ultrasound stimuli for enhancing the antitumor effect via PAI/MRI monitoring, which provides an ideal strategy for developing multifunctional Fenton nanoplatform in future clinical applications.

**Other imaging modality-guided cancer theranostics**

Surface-enhanced Raman scattering (SERS) can provide molecular fingerprint information in various cells and tissues [250]. SERS possesses remarkable advantages, including being non-invasive and having ultrahigh specificity and resolution, and resistance to autofluorescence and photobleaching [251]. In an interesting study, paraaminothiophenol (PATP) and hemin were decorated on gold NP (Au@PATP/Hemin) to detect ·OH, O₂⁻, ROO⁻, and ·O₂ directly, and H₂O₂ indirectly [252]. H₂O₂ was converted into ·OH via hemin-catalyzed Fenton reaction, and PATP reacted with ·OH, O₂⁻, ROO⁻ or ·O₂ by a radical oxidant coupling reaction to form 4,4'-dimer-captoazobenzene (DMAB), eliciting new Raman peaks for quantitative detection. The nanoprobes were sensitive and quantitative, showing promise to monitor tumor development and inflammation progression, and guide therapies.

The capture and inactivation of circulating tumor cells (CTCs) in blood vessels have been regarded as a promising strategy to inhibit tumor metastasis [253]. Thus, in one study, an all-in-one nanoplatform was prepared as a signal probe and CDT agent by integrating magnetic MOF (magMOF) NPs with TiO₂ nanotube arrays (TiNTs) [254]. The magMOF NPs were constructed by encapsulating Fe₃O₄ with a MIL-100(Fe) shell, and then the GOD was loaded into the magMOF NPs. The gluconic acid generated by GOD enhanced TME acidity, therefore prompting the dissolution of MIL-100(Fe) to produce Fe³⁺, and then effectively improved the cell killing efficiency via the Fenton-like reaction. Attractively, the CTCs were magnetically captured and collected onto TiNTs. TINT photocatalysis activated the release of Fe³⁺ and produced exogenous ·OH radicals, which could be measured by pulse voltammetry and TINTs as the electrode. The intensities of differential pulse voltammetry were correlated with CTC numbers ranging from 2 to 5000 cell mL⁻¹. This material provides a novel method for constructing multifunctional chips for CTC capture and early tumor diagnosis.

**Multi-modality imaging-guided cancer theranostics**

Precisely locating the tumor site and achieving whole-body visualization based on multimodal imaging have garnered extensive research attention for accurate and efficient antitumor therapy [255]. In one investigation, pure phase bismuth ferrite nanocatalysts (BFO NCs) were prepared for multimodal imaging-guided Fenton effect against malignant tumors [256]. The prepared BFO NCs showed excellent physiological stability and biocompatibility in the blood circulation. Interestingly, the external ultrasound assistance enhanced the ROS generation of BFO NCs, owing to the partial grievous turbulence of cavitation bubbles triggered by ultrasound, thereby promoting the transfer efficacy of the Fenton reagents. Meanwhile, the BFO NCs exhibited superior fluorescence intensity within the NIR-II laser. Besides, the high X-ray attenuation coefficient (5.74 cm²/kg at 100 kV) and intrinsic magnetic performance of Bi rendered BFO NCs an excellent contrast agent for CT imaging and MRI. According to the in vitro and in vivo results, the BFO NCs effectively inhibited tumor growth under the external ultrasound assistance, which was precisely monitored by fluorescence imaging, CT, and MRI. Overall, the BFO NCs presented multimodality imaging capacity and enhanced Fenton therapeutic effect, offering a promising prospect for precise and non-invasive antitumor therapy.

In the recent years, lanthanide-based downconversion NPs (DCNPs) have attracted attention because of their unique characteristics, including high stability, long luminescence lifetimes, low photobleaching, and precisely controlled size [257]. To achieve high-resolution real-time tumor observation and whole-body visualization, biodegradable copper/manganese silicate nanosphere-coated lanthanide-doped NPs (LDNPs@CMCNs) were developed for trimodal imaging (NIR-II, MRI, and CT) guided CDT/PDT combination therapy in one study [258]. The Yb³⁺/Er³⁺/Tm³⁺ were doped in the core and
Yb³⁺/Ce³⁺ in the shell, enabling the ultraefficient upconversion and downconversion emissions of LDNPs upon NIR light excitation. In the hypoxic tumor, the GSH-responsive CMSNs were degraded and released Mn²⁺ and Cu⁺ ions for Fenton-like •OH generation. The Ce³⁺ and Er³⁺, were doped in the shell and core of LDNPs, respectively, allowing NIR-II imaging. In addition, lanthanide-doped DCNPs allowed T1 MRI and CT imaging. The TME-responsive release of Mn²⁺, together with self-amplified trimodal bioimaging (NIR-II luminescence imaging, MRI, and CT) makes this approach greatly promising for highly efficient tumor theranostics.

Lastly, in one study, using biodegradable manganese carbonate NPs, the release of Mn²⁺ and CO₂ gas can be triggered by acidic TME and the released Mn²⁺ and CO₂ can allow for MR and ultrasound imaging of tumors, respectively [259].

Conclusions and outlook
In recent years, many studies have described innovative strategies to treat cancer on the basis of Fenton and Fenton-like reactions. This review summarizes the latest developments in Fenton and Fenton-like reactions by analyzing the purpose and mechanism of Fenton and Fenton-like reaction-based nanomaterials. Fenton and Fenton-like reactions can adequately exert their potential when combined with other therapeutic strategies, providing specific, efficient, and safe protocols for cancer treatment. Fenton and Fenton-like reaction-based nanomaterials can also be used for accurate tumor diagnosis and for monitoring tumor growth and guiding the therapy of cancers in the clinic using different imaging modalities such as MRI, CT, and PAI.

There has been significant progress in the development of Fenton and Fenton-like reaction-based nanomaterials; however, there are some problems which need to be solved in order for them to be used clinically. (i) The stability, biocompatibility, and biosafety of Fenton and Fenton-like agents need to be improved. Ultrasmall or biodegradable CDT-based nanomaterials which can be removed from the body and which exhibit a rapid metabolism can achieve better clinical safety. And relative to inorganic nanomaterials, organic molecules are more degradable and some of them also exhibit the potential of triggering Fenton and Fenton-like reactions. Therefore, the exploration of organic molecules with properties of Fenton and Fenton-like reactions may provide extra opportunities to discover biocompatible Fenton and Fenton-like agents. (ii) The traditionally understood mechanism of the Fenton and Fenton-like reactions may not adequately explain their reactions in a complicated physiological system. More attention should be paid to monitor in situ Fenton reactions and Fenton-like reactions process via on-line characterization techniques, thereby optimizing their antitumor efficacy and enhancing their clinical applications. (iii) Fenton and Fenton-like reactions can generate O₂ to alleviate the tumor hypoxia, which is a main restriction in clinical radiotherapy. However, the exploration of their combination with other therapeutic strategies is still lacking. In addition, in improve therapeutic efficacy, CDT-based combination therapy with genetic or molecular methodologies should also be explored. (iv) The TME responsive agents of Fenton and Fenton-like reactions have exhibited improved specificity, efficacy, and safety for tumor therapy. However, there remains an urgent need to design personalized TME responsive agents for different tumors microenvironments, which will benefit their clinical translation.

Although Fenton and Fenton-like reactions-mediated synergistic strategies for cancer therapy face several challenges, the clinical translation of Fenton and Fenton-like reactions-based nanomedicines are still promising, especially after their current drawbacks have been addressed in the future.

Acknowledgements
Not applicable.

Authors’ contributions
JX, CD and OA wrote and revised the manuscript, FA, CW and MZ conceived the idea, revised and corrected the manuscript, JX prepared graphical section. All the authors have read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (51903201), China Postdoctoral Science Foundation Grant (2019M653660), and Fundamental Research Funds for the Central Universities (jcyj2019077). OA was partially supported through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Declarations

Consent for publication
All authors agree to be published.

Competing interests
The authors declare no conflict of interest, financial or otherwise.

Author details
1Institute of Medical Engineering, Department of Biophysics, School of Basic Medical Science, Health Science Center, Xi’an Jiaotong University, No. 76 Yanta West Road, Xi’an, Shaanxi 710061, People’s Republic of China. 2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. 3Department of Pharmacology, School of Pharmacy, Nantong University, 226010 Nantong, Jiangsu, People’s Republic of China.

Received: 25 March 2021  Accepted: 13 June 2021  Published online: 28 June 2021

References
1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship
2. Sang W, Zhang Z, Dai Y, Chen X. Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem Soc Rev. 2019;48(14):7771–810. https://doi.org/10.1039/C9CS00896E.

3. Chen Q, Chen J, Yang Z, Xu J, Xu L, Liang C, Han X, Liu Z. Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv Mater. 2019;31(10):1802228. https://doi.org/10.1002/adma.201802228.

4. Lo P-C, Rodríguez-Morgade MS, Pandey RK, Ng DKP, Torres T, Dumoulin F. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer. Chem Soc Rev. 2020;49(4):1041–56. https://doi.org/10.1039/C9CS0129H.

5. Du C, Zhou M, Jia F, Ruan L, Hu H, Jiang Z, Zou B, Liu X, Chen J, Chai Z, Hu Y. Arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy. Biomaterials. 2021. https://doi.org/10.1016/j.biomaterials.2021.08.010.

6. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51. https://doi.org/10.1038/nbt.3330.

7. Vasian N, Baselgia, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7347):299–309. https://doi.org/10.1038/s41586-019-1730-1.

8. Sha H, Zhang B, Liang T, Ding J, Min Q, Zhu J. Promoting oxidative stress in cancer starvation therapy by site-specific startup of hyaluronic acid-encapsulated dual-catalytic nanoreactors. ACS Appl Mater Interfaces. 2019;11(21):18995–9005. https://doi.org/10.1021/acsami.9b06034.

9. Wang D, Zhou J, Chen R, Shi R, Xia G, Zhou S, Liu Z, Zhang N, Wang H, Guo Z, Chen Q. Magnetically guided delivery of DHA and Fe ions for enhanced cancer therapy based on pH-responsive degradation of DHA-loaded Fe3O4/C@MIL-100(Fe) nanoparticles. Biomaterials. 2016;107:88–101. https://doi.org/10.1016/j.biomaterials.2016.08.039.

10. Li Y, Zhao P, Gong T, Wang H, Jiang X, Cheng H, Liu Y, Wu Y, Bu W. Redox dyshomeostasis strategy for hypoxic tumor therapy based on dnazyme-loaded electrophilic zifs. Angew Chem Int Ed. 2020;59(50):22537–43. https://doi.org/10.1002/anie.202003635.

11. Min H, Qi Y, Zhang Y, Han X, Cheng K, Liu Y, Liu H, Hu J, Nie G, Li Y. A graphylene oxide-based iron sponge with photothermally enhanced tumor-specific fenton chemistry. Adv Mater. 2020;32(31):2000338. https://doi.org/10.1002/adma.202000338.

12. Lin J, He T, Yuan Y, Jiang C, Blum NT, He J, Huang P. Light-triggered transformable ferrous ion delivery system for photothermal primed chemodynamic therapy. Angew Chem Int Ed. 2021;60(1):6047–54. https://doi.org/10.1002/anie.202015379.

13. Liu Y, Jiang Y, Zhang M, Tang Z, He M, Bu W. Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors. Acc Chem Res. 2018;51(10):2502–11. https://doi.org/10.1021/acs.accounts.8b00214.

14. Liu M-D, Guo D-K, Zeng R-Y, Ye J-J, Wang S-B, Li C-X, Sun Y-X, Cheng S-X, Zhang X-Z. Yolk-shell structured nanoflowers induced intracellular oxidative/differential stress damage for cancer treatment. Adv Funct Mater. 2020;30(51):2006098. https://doi.org/10.1002/adfm.202006098.

15. Chen Q, Liu X, Chen J, Zeng J, Chen Z, Liu Z. A self-assembled albumin-based nanoprobe for in vivo ratiometric photoacoustic ph imaging. Adv Mater. 2015;27(43):6820–7. https://doi.org/10.1002/adma.201503194.

16. Lin H, Chen Y, Shi J. Nanoparticle-triggered in situ catalytic chemical reactions for tumour-specific therapy. Chem Soc Rev. 2018;47(6):1938–58. https://doi.org/10.1039/C8CS00471H.

17. Niu X, Liu W, Wang W, Yuan Z. NIR light-driven Bi2Se3 nanorod-nanorod array with “three in one” herin-assisted cascade catalysis for synergistic cancer therapy. Adv Funct Mater. 2020;30(52):2006883. https://doi.org/10.1002/adfm.202006883.

18. Chen Q, Shan X, Sh X, Jiang C, Li T, Wei S, Zhang X, Sun G, Liu J. Tumor microenvironment-responsive polyphosphazene-based core/shell nanoplatform for synergetic theranostics. J Mater Chem B. 2020;8(18):4056–66. https://doi.org/10.1039/D0TB00248H.

19. Goldstein S, Meyerstein D, Czapski G. The fenton reagents. Free Radic Biol Med. 1993;15(4):435–45. https://doi.org/10.1016/0891-5849(93)90043-4.

20. Walling C. Intermediates in the reactions of fenton type reagents. Free Radic Biol Med. 2019;120:1681–90. https://doi.org/10.1016/j.freeradbiomed.2019.02.002.

21. Yu W, Shevtsov M, Chen X, Gao H. Advances in aggregateable nanomaterials for tumor-targeted drug delivery. Chin Chem Lett. 2020;31(12):3027–40. https://doi.org/10.1016/j.ccl.2020.05.027.

22. Zeng P, Liu Y, Chen J, Xu W, Li G, Ding J. Targeted pH-responsive polymer complex micelle for controlled intracellular drug delivery. Chin Chem Lett. 2020;31(5):1178–82. https://doi.org/10.1016/j.ccl.2019.12.001.

23. Yu W, Shevtsov M, Chen X, Gao H. Advances in aggregateable nanoparticle for tumor-targeted drug delivery. Chin Chem Lett. 2020;31(6):1366–74. https://doi.org/10.1016/j.ccl.2020.02.036.

24. Duan L-Y, Wang Y-J, Liu J-W, Lu N, Jiang J-H. Tumor-selective catalytic nanosystem for activatable theranostics. Chem Commun. 2018;54(59):8214–7. https://doi.org/10.1039/C8CC03922D.

25. Sun X, Zhang G, Du R, Rui Z, Zhao C, Bai G, Yang C, Zhang Z, Zhang X, Zou D, Wu Z. A biodegradable MnS@Fe3O4 platform for dual-mode magnetic resonance imaging guided combinational cancer therapy. Biomaterials. 2019;194:151–60. https://doi.org/10.1016/j.biomaterials.2018.12.002.

26. Xiao J, Zhang G, Xu R, Chen H, Tian G, Wang B, Yang C, Bai G, Zhang Z, Yang H, Zou D, Wu Z. A programmable system combining chemodynamic therapy with limotherapy for simultaneous bioimaging and synergistic cancer therapy. Biomaterials. 2019;216:119254. https://doi.org/10.1016/j.biomaterials.2019.119254.

27. Fan X, Peng M-Y, Wang H, Zheng H-R, Liu Z-W, Li C-X, Wang X-N, Liu X-H, Cheng S-X, Zhang Z. Biomedical materials: engineered bacterial biocatalyst for tumor therapy via fenton-like reaction with localized H2O2 generation. Adv Mater. 2019;31(16):1970119. https://doi.org/10.1002/adma.201907019.

28. Finkel T. Signal transduction by reactive oxygen species in non-phagocytic cells. J Leukoc Biol. 1999;65(3):337–40. https://doi.org/10.1002/jlb.33.6.137.

29. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid
Redox Biol. 2019;60(1):1295–322. https://doi.org/10.1016/j.redox.2019.07.018.

43. Han Y, Gao S, Zhang Y, Ni Q, Li Z, Liang XJ, Zhang J. Metal-based nanocatalyst for combined cancer therapeutic. Bioconjug Chem. 2020;31(1):1–10. https://doi.org/10.1021/acs.biomac.9b01478.

44. Liu J, Zhang Y, Cao Y, Gao T, Kuang Y, An Z, Mao Z, He Y, Yan J, Lu P, Wei R. Tumor microenvironment-responsive and catalytic cascade-enhanced nanocomposite for tumor thermal ablation synergizing with chemodynamic/photothermal therapy. Biomater. 2021;266:120429. https://doi.org/10.1016/j.biomaterials.2021.120277.

45. Wang X, Zheng W, Chen X, Shen Y, Zhang H, Peng P. A magnetofluorescent carbon dot assembly as an acidic H2O2-driven oxygenator to regulate tumor hypoxia for simultaneous bimodal imaging and enhanced photodynamic therapy. Adv Mater. 2018;30(13):1706090. https://doi.org/10.1002/adma.201706090.

46. Zhao Z, Xu K, Fu C, Liu H, Li M, Bao J, Fu A, Yu Y, Zhang W. Interfacial engineered gadolinium oxide nanoparticles for magnetic resonance imaging guided microenvironment-mediated synergetic chemodynamic/photothermal therapy. Biomater. 2019;119:7399. https://doi.org/10.1016/j.biomaterials.2019.119379.

47. Zhu P, Chen Y, Shi J. NANOzyme-enhanced cancer sonodynamic therapy by catalytic tumor oxygenation. ACS Nano. 2018;12(4):3780–95. https://doi.org/10.1021/acsnano.7b07680.

48. Wang Y, Song M. Responsive cascaded nanocatalyst for synergistic like-starvation and chemodynamic therapy. Colloids Surf B Biointerfaces. 2020;192:111029. https://doi.org/10.1016/j.colsurfb.2020.111029.

49. Wang X, Zhong X, Lei H, Geng Y, Zhao Q, Gong F, Yang Z, Dong Z, Liu Z, Zhang X. Catalytic Cu2OSe nanosheets for tumor photo-thermal-catalytic therapy. Chem Mater. 2019;31(16):6174–86. https://doi.org/10.1021/acs.chemmater.9b01958.

50. Ni K, Lan G, Chan C, Quigley B, Lu K, Aung T, Guo N, La Riviere P, Weichselbaum RR, Lin W. Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun. 2018;9(1):2351. https://doi.org/10.1038/s41467-018-04703-w.

51. Zhang K, Meng X, Yang Z, Dong H, Zhang X. Enhanced cancer therapy by hypoxia-responsive copper metal-organic frameworks nanosystem. Biomater. 2020;258:120278. https://doi.org/10.1016/j.biomaterials.2020.120278.

52. Gelson RC, Black KL, Lane DD, Achillefu S. Hybrid TiO2–ruthenium nano-photosensitizer synergistically produces reactive oxygen species in both hypoxic and normoxic conditions. Angew Chem Int Ed. 2017;56(36):10717–20. https://doi.org/10.1002/anie.201704458.

53. Mei L, Ma D, Gao Q, Zhang X, Fu W, Dong X, Xing G, Yin W, Gu Z, Zhao Y. Glucose-responsive cascaded nanocatalytic reactor with self-modulation of the tumor microenvironment for enhanced chemo-catalytic therapy. Mater Horiz. 2020;7(7):1834–44. https://doi.org/10.1039/D0MH01372B.

54. Dai Y, Yang Z, Zheng S, Wang Z, Zhang R, Zhu G, Wang Z, Yang BC, Tian R, Jacobson O, Xu C, Ni Q, Song J, Sun X, Niu G, Chen X. Toxic reactive oxygen species enhanced synergistic combination therapy by self-assembled metal-phenolic network nanoparticles. Adv Mater. 2018;30(8):1704385. https://doi.org/10.1002/adma.201804385.

55. Shi L, Han K, Guo H, Zhang R, Yang Z, Cheng S, Wang Z, Zhang R, Zhu G, Yang H, He Y, Shen Y, Qiu H. Heparanase-driven sequential released nanoparticles for ferroptosis and tumor microenvironment modulations synergism in breast cancer therapy. Biomater. 2021;266:120429. https://doi.org/10.1016/j.biomaterials.2020.120429.

56. Liu X, Xu G, Gao T, Xu M, Huang X, Xie J, Zhang J, Gao S, Zhang Y, Ni Q, Song J, Sun X, Niu G, Chen X. Toxic reactive oxygen species enhanced synergistic combination therapy by self-assembled metal-phenolic network nanoparticles. Adv Mater. 2018;30(8):1704385. https://doi.org/10.1002/adma.201804385.

57. Dai Y, Yang Z, Zheng S, Wang Z, Zhang R, Zhu G, Wang Z, Yang BC, Tian R, Jacobson O, Xu C, Ni Q, Song J, Sun X, Niu G, Chen X. Toxic reactive oxygen species enhanced synergistic combination therapy by self-assembled metal-phenolic network nanoparticles. Adv Mater. 2018;30(8):1704385. https://doi.org/10.1002/adma.201804385.

58. Sun L, Xu G, Gao T, Xu M, Huang X, Xie J, Zhang J, Gao S, Zhang Y, Ni Q, Song J, Sun X, Niu G, Chen X. Toxic reactive oxygen species enhanced synergistic combination therapy by self-assembled metal-phenolic network nanoparticles. Adv Mater. 2018;30(8):1704385. https://doi.org/10.1002/adma.201804385.
agent for cancer. ACS Appl Mater Interfaces. 2018;10(45):38833–44. https://doi.org/10.1021/acsami.8b15678.

71. Wang X, Zhong X, Bai L, Xu J, Gong F, Dong Z, Yang Z, Zeng Z, Liu Z, Cheng L. Ultrafine titanium monoxide (TiO1.2) nanorods for enhanced somaticodynamic therapy. J Am Chem Soc. 2020;142(14):6527–37. https://doi.org/10.1021/jacs.9b10228.

72. Wang M, Chang M, Chen Q, Wang D, Li C, Hou Z, Lin J, Jin D, Xing B. Au,Pr-Pt-PEG-C6 nanof ormulation with dual nanozyme activities for synergic chemodynamic therapy/phototherapy. Biomaterials. 2020;252:120093. https://doi.org/10.1016/j.biomaterials.2020.120093.

73. Bokare AD, Choi W. Review of iron-free fenton-like systems for activating H2O2 in advanced oxidation processes. J Hazard Mater. 2014;275:121–35. https://doi.org/10.1016/j.jhazmat.2014.04.054.

74. Li M, Zhang H, Hou Y, Wang X, Xue C, Li W, Cai K, Zhao Y, Luo Z. State-of-the-art iron-based nanozymes for biocatalytic tumor therapy. Nanoscale Horiz. 2020;5(2):202–17. https://doi.org/10.1039/c9nh00577c.

75. Zhang C, Bu W, Ni D, Zhang S, Li Q, Yao Z, Zhang J, Yao H, Wang Z, Shi J. Synthesis of iron nanometallic glasses and their application in cancer therapy with a localized fenton reaction. Angew Chem Int Ed. 2016;55(6):2101–6. https://doi.org/10.1002/anie.201510031.

76. Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, Zhang S-B, Feng J, Zhang X-Z. Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano. 2018;12(12):12181–92. https://doi.org/10.1021/acsnano.8b05860.

77. Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Chen JH, Clemons PA, Shanji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL. Regulation of ferroptotic cancer cell death by gpX4. Cell. 2014;156(2–3):317–31. https://doi.org/10.1016/j.cell.2014.02.030.

78. Yang W, Sriri Maratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Chen JH, Clemons PA, Shanji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL. Regulation of ferroptotic cancer cell death by gpX4. Cell. 2014;156(2–3):317–31. https://doi.org/10.1016/j.cell.2014.02.030.

79. Mei X, Hu T, Wang H, Liang R, Bu W, Wei M. Highly dispersed nanoenzyme triggered intracellular catalytic reaction toward cancer specific therapy. Biomaterials. 2020;258:120257. https://doi.org/10.1016/j.biomaterials.2020.120257.

80. Wang Y, Liu X, Dong S, Kuang Y, Dong H, He F, Gai S, Yang P. Fusi form-like copper(II)-based metal-organic framework through relief hypoxia and GSH-depletion co-enhanced starvation and chemodynamic synergetic cancer therapy. ACS Appl Mater Interfaces. 2020;12(15):17254–67. https://doi.org/10.1021/acsami.0c13519.

81. Mei X, Hu T, Wang H, Liang R, Bu W, Wei M. Highly dispersed nanoenzyme triggered intracellular catalytic reaction toward cancer specific therapy. Biomaterials. 2020;258:120257. https://doi.org/10.1016/j.biomaterials.2020.120257.

82. Zhu J, Dai P, Liu F, Li Y, Qin Y, Yang Q, Tian R, Fan A, Medeiros SDF, Wang XH. A smart nanoparticle-ergistic chemodynamic therapy/phototherapy. Biomaterials. 2020;252:doi.org/10.1016/j. biomaterials.2020.120257.

83. Sun P, Deng Q, Kang L, Sun Y, Ren J, Qu X. A novel Mn-Cu bimetallic complex for enhanced chemodynamic therapy with simultaneous glutathione depletion and use of a fenton nanocatalyst for enhanced chemodynamic therapy. ACS Appl Mater Interfaces. 2019;11(34):30551–65. https://doi.org/10.1021/acsami.9b09323.

84. Chen Q, Zhou J, Chen Z, Luo Q, Xu J, Song G. Tumor-specific expansion of oxidative stress by glutathione depletion and use of a fenton nanocatalyst for enhanced chemodynamic therapy. ACS Appl Mater Interfaces. 2019;11(34):30551–65. https://doi.org/10.1021/acsami.9b09323.

85. Wang Z, Liu B, Sun Q, Dong S, Kuang Y, Dong H, He F, Gai S, Yang P. Fusi form-like copper(II)-based metal-organic framework through relief hypoxia and GSH-depletion co-enhanced starvation and chemodynamic synergetic cancer therapy. ACS Appl Mater Interfaces. 2020;12(15):17254–67. https://doi.org/10.1021/acsami.0c13519.

86. Zhao S, Wang J, Yang L, Chen X, Liang R, Bu W, Wei M. Highly dispersed nanoenzyme triggered intracellular catalytic reaction toward cancer specific therapy. Biomaterials. 2020;258:120257. https://doi.org/10.1016/j.biomaterials.2020.120257.

87. He Y-J, Liu X-Y, Xing L, Wan X, Chang X, Jiang H-L. Fenton reaction-independent ferropototic therapy via glutathione and iron redox coupling sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:1199911. https://doi.org/10.1016/j.biomaterials.2020.1199911.

88. Chen Q, Zhou J, Chen Z, Luo Q, Xu J, Song G. Tumor-specific expansion of oxidative stress by glutathione depletion and use of a fenton nanocatalyst for enhanced chemodynamic therapy. ACS Appl Mater Interfaces. 2019;11(34):30551–65. https://doi.org/10.1021/acsami.9b09323.
104. Hu R, Fang Y, Huo M, Yao H, Wang C, Chen Y, Wu R. Ultrasound CuxS
nanodots as photothermal-enhanced fenton nanocatalysts for syner-
gistic tumor therapy at NIR-II biowindow. Biomaterials. 2019;206:101–14.
https://doi.org/10.1016/j.biomaterials.2019.03.014.

105. Tang W, Gao H, Ni D, Wang Q, Gu B, He X, Peng W. Bovine serum album-
in-templated nanoplatform for magnetic resonance imaging-guided
chemodynamic therapy. J Nanobiotechnol. 2019;17(1):68. https://doi.
org/10.1186/s12951-019-0501-3.

106. Ma B, Wang S, Liu F, Zhang S, Duan J, Li Z, Kong Y, Yang Y, Liu H, Bu
W, Li L. Self-assembled copper-omega acid nanoparticles for in situ
glutathione and H2O2 sequencially triggered chemodynamic therapy.
J Am Chem Soc. 2018;141(2):849–57. https://doi.org/10.1021/jacs.8b0874.

107. Lu X, Gao S, Lin H, Yu L, Han Y, Zhu P, Chen L, Wu J, Wu H, Zhao M,
Zhang Y, Chen Z, Yu J, Shi Z, Ji Y. Bioin-
pired copper single-atoms catalysts for tumor parallel catalytic therapy.
Adv Mater. 2020;32(5):2002246. https://doi.org/10.1002/adma.2020
20246.

108. Dong Z, Yang Z, Hao Y, Feng L. Fabrication of H2O2-driven nanoreactors
for innovative cancer treatments. Nanoscale. 2019;11(35):16164–86.
https://doi.org/10.1039/c9nr04418c.

109. Ju Y, Dong B, Yu J, Hou Y. Norganic nanomaterials for imaging-guided
cancer therapy. Nano Today. 2019;26:108–12. https://doi.org/10.1016/j.
jnodot.2019.03.006.

110. Zhao S, Liu Y, Liu H, Cheng S, Zheng C, Sun Z, Du Y, Butch CJ, Wei
H. An orally administrated Ce6@montmorillonite nanozymes targets
inflammation for inflammatory bowel disease therapy. Adv Funct Mater.
2020;30(54):2004692. https://doi.org/10.1002/adfm.202004692.

111. Li Y, Jia R, Lin H, Sun Q, Fu Y. Synthesis of MoSe2/CoSe2 nanosheets for
nir-enhanced chemodynamic therapy via synergistic in-situ H2O2 pro-
duction and activation. Adv Funct Mater. 2021;31(8):2008420. https:
//doi.org/10.1002/adfm.20208420.

112. Xie Z, Liang S, Cai X, Ding B, Huang S, Hou Z, Ma P, Cheng Z, Lin J.
O2–/Cu2ZIF–88Ce/BiFeO3 composite as a tumor microenviron-
ment-responsive nanoplatform with enhanced photo-/chemodynamic
antitumor efficacy. ACS Appl Mater Interfaces. 2019;11;58(40):14134–9.
https://doi.org/10.1021/acsami.9b10685.

113. Shen Z, Liu T, Liu H, Chen L, Wu J, Wu H, Zhao M, Chen J, Liu C, Ren
X, Ma R, Ma X, Kim D, Sun J, Davis TR, Chen T, Tian J, Hyeon T, Ling
D. Arginine-rich manganese silicate nanobubbles as a ferro-
topsis-inducing agent for tumor-targeted therapies. ACS Nano.
2018;12(12):13895–94. https://doi.org/10.1021/acsnano.8b05836.

114. Wang S, Yu G, Zhang J, Jacobson O, Lin L-S, Yang W, Deng H, He Z, Liu Y,
Chen Z-Y, Chen X. Enhanced antitumor efficacy by a cascade of reactive
oxygen species generation and drug release. Angew Chem Int Ed.
2019;58(41):14758–63. https://doi.org/10.1002/anie.201908997.

115. Wang S, Li F, Qiao R, Huang W, Liao H, Chen L, Wu J, Wu H, Zhao M,
Zhou Y, Liu J, Chen R, Ma X, Kim D, Sun J, Davis TR, Chen T, Tian J, Hyeon T,
Ling D. Arginine-rich manganese silicate nanobubbles as a ferro-
topsis-inducing agent for tumor-targeted therapies. ACS Nano.
2018;12(12):13895–94. https://doi.org/10.1021/acsnano.8b05836.

116. Shenh Z, Liu T, Li Y, Liu J, Yang Z, Fan W, Zhou Z, Shu C, Ke C, Bregadze VI,
Mandal SK, Liu Y, Li Z, Xue T, Zhu G, Munasinghe J, Niu Q, Wu A, Chen X.
Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis-
therapy of orthotopic brain tumors. ACS Nano. 2018;12(1):11355–65.
https://doi.org/10.1021/acsnano.8b06201.

117. Ma PA, Xiao H, Yu C, Liu J, Cheng Z, Song H, Zhang X, Li C, Wang J, Gu
Z, Lin J. Enhanced cисplatin chemotherapy by iron oxide nanocarrier-
mediated generation of highly toxic reactive oxygen species. Nano Lett.
2017;17(2):928–37. https://doi.org/10.1021/acs.nanolett.6b04269.

118. Ren Z, Sun S, Sun R, Cui G, Hong L, Yao B, Li A, Yu Z, Kan Q, Mao Z. A
metal-polyphenol-coordinated nanomedicine for synergistic carcass
chemotherapy and chemodynamic therapy. Adv Mater. 2020;32(6):
e1906024. https://doi.org/10.1002/adma.201906024.

119. Chen Y, Yao Y, Zhou X, Liao C, Dai X, Liu J, Yu Y, Zhang S. Cascade-reac-
tion-based nanodrug for combined chemo/starvation/chemodynamic
therapy against multidrug-resistant tumors. ACS Appl Mater Interfaces.
2019;11(19):46112–23. https://doi.org/10.1021/acsami.9b15848.

120. Ding B, Shao S, Jiang F, Deng P, Sun C, Huang S, Ma P, Jin D, Kheraif
AAA, Lin J. MnOx-disguised upconversion hybrid nanocomposite: an
ideal architecture for tumor microenvironment-triggered ucl-
ir bioimaging and enhanced chemodynamic therapy. Chem Mater.
2019;31(7):2651–60. https://doi.org/10.1021/acs.chemmater.9b00893.

121. Wang S, Wang Z, Yu G, Zhou Z, Jacobson O, Liu Y, Ma Y, Zhang F, Chen
ZY, Chen X. Tumor-specific drug release and reactive oxygen species
generation for cancer chemo/chemodynamic combination therapy.
Adv Sci. 2019;6(5):e1801986. https://doi.org/10.1002/advs.201801986.

122. Ding Y, Xu H, Xu C, Tong Z, Zhang S, Bai Y, Chen Y, Xu Q, Zhou L, Ding
H, Sun Z, Yan S, Mao Z, Wang W. A nanomedicine fabricated from gold
nanoparticles-decorated metal–organic framework for cascade chemo/
chemodynamic cancer therapy. Adv Sci. 2020;7(17):2001060. https:
//doi.org/10.1002/advs.202001060.

123. Ke W, Li J, Mohammad F, Wang Y, Tou K, Liu X, Wen F, Kinoh H, Anraku
Y, Chen H, Katoaka K, Ge Z, Therapeutic polymersome nanoreactors
with tumor-specific activable cascade reactions for cooperative cancer
therapy. ACS Nano. 2019;13(2):2357–69. https://doi.org/10.1021/acsnano.
8b09082.

124. Guo Y, Jia H-R, Zhang X, Zhang X, Sun Q, Wang S-Z, Zhao J, Wu F-G.
A glucose/oxygen-exhausting nanoractor for starvation- and hypoxia-
activated sustainable and cascade chemo-chemodynamic therapy.
Adv Mater. 2020;32(16):2000807. https://doi.org/10.1002/adma.202000807.

125. Cheng K, Ling C, Guo D, Gao Z, Li Y, An P, Zhang Y, You C, Zhang R, Sun
B. Multimodal therapies: glucose oxidase-triggered tumor starvation-
induced synergism with enhanced chemodynamic therapy and
ferroptosis in solid tumors. Biomaterials. 2021;268:120537. https://doi.
org/10.1016/j.biomaterials.2020.120537.
151. Wang D, Feng L, Chao Y, Hao Y, Chen M, Gong F, Han X, Zhang R, Cheng L, Liu Z. Amplification of tumor oxidative stresses with liposomal fenton-reactive iron catalyst and glutathione inhibitor for enhanced cancer chemotherapy and radiotherapy. Nano Lett. 2019;19(2):805–15. https://doi.org/10.1021/acs.nanolett.8b03905.

152. Li R, Chen Y, Hua M, Zhang J, Li Y. Sequential catalytic nanomedicine augments synergistic chemodrug and chemodynamic cancer therapy. Nanoscale Horiz. 2019;4(4):890–901. https://doi.org/10.1039/C9NH0008A.

153. Dong Z, Feng L, Chao Y, Hao Y, Chen M, Gong F, Han X, Zhang R, Cheng L, Liu Z. Amplification of tumor oxidative stresses with liposomal fenton-reactive iron catalyst and glutathione inhibitor for enhanced cancer chemotherapy and radiotherapy. Nano Lett. 2019;19(2):805–15. https://doi.org/10.1021/acs.nanolett.8b03905.

154. Xu T, Ma Y, Yuan Q, Hu H, Hu X, Qian Z, Rolle JK, Gu Y, Li S. Enhanced ferropotosis by oxygen-boosted phototherapy based on a 2-in-1 nanoplatform of ferrous hemoglobin for tumor synergistic therapy. ACS Nano. 2020;14(3):3414–25. https://doi.org/10.1021/acs.nanolett.9b04926.

155. Li L, Zhang Y, Fan W, He L, Cui C, Zou J, Tang W, Jacobson O, Wang Z, Niu G, Hu S, Chen X. In situ polymerized hollow mesoporous organosilica biocatalysis nanoreactor for enhancing ros-mediated anticancer therapy. Adv Funct Mater. 2020;30(4):1907716. https://doi.org/10.1002/adfm.201907716.

156. Sun S, Chen Q, Tang Z, Liu C, Li Z, Wu A, Lin H. Tumor microenvironment-stimuli-responsive fluorescence imaging and synergistic cancer therapy by carbon-dot-Cu2+ nanoassemblies. Angew Chem Int Ed. 2020;59(47):21041–8. https://doi.org/10.1002/anie.202007786.

157. Al X, Hu M, Wang Z, Lyu L, Zhang W, Li J, Yang H, Lin J, Xing B. Enhanced cellular ablation by attenuating hypoxia status and reprogramming tumor-associated macrophages via nr light-responsive upconversion nanocrystals. Bioconjug Chem. 2018;29(4):928–38. https://doi.org/10.1021/acs.bioconjugchem.8b00668.

158. Huang Y, Jiang Y, Xiao Z, Shen Y, Huang L, Xu X, Wei G, Xu C, Zhao C. Three birds with one stone: a ferric pyrophosphate based nanogent for synergistic NRT-triggered photo/chemodynamic therapy with glutathione depletion. Chem Eng J. 2020;380:122369. https://doi.org/10.1016/j.cej.2019.122369.

159. Huang Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanothrombostics in fighting cancer. Chem Soc Rev. 2019;48(7):2053–108. https://doi.org/10.1039/c8cs00271d.

160. Bhattarai P, Zhang C, Wang W, Chu Z, Zha H, Xue W, Zhao W, Liu T, Wang H, Qian H. Ultrastable Agβ2S hollow nanospheres with cancer cell-specific cytotoxicity for multimodal tumor therapy. ACS Nano. 2020;14(11):14919–28. https://doi.org/10.1021/acs.nanolett.9b09426.

161. Chang M, Hou Z, Jin D, Zhou J, Wang M, Wang M, Shu M, Ding B, Li C, Lin J. Colorectal tumor microenvironment-activated bio-decomposable and metabolizable Cu2O@CaCO3 nanocomposites for synergistic oncotherapy. Adv Mater. 2020;32(43):2004647. https://doi.org/10.1002/adma.202004647.

162. Zhang L, Wang D, Yang K, Sheng D, Tan B, Wang Z, Ran H, Yi H, Zhong Y, Lin H, Chen Y. Mitochondria-targeted artificial “nano-RBCs” for amplified synergetic cancer phototherapy by a single NIR irradiation. Adv Sci. 2018;5(8):1800049. https://doi.org/10.1002/advs.201800049.

163. An F, Yang Z, Zheng M, Mei T, Deng G, Guo P, Li Y, Sheng R. Rationally assembled albumin/iodoynene green nanocomplex for enhanced tumor imaging to guide photothermal therapy. J Nanobiotechnol. 2020;18(1):49. https://doi.org/10.1186/s12951-020-00603-8.

164. Li S, Deng Q, Zhang Y, Li X, Wen G, Cui X, Wan Y, Huang Y, Chen J, Liu Z, Wang L, Lee C-S. Rational design of conjugated small molecules for superior photothermal theranostics in the NIR-II biowindow. Adv Sci. 2020;7(33):2001146. https://doi.org/10.1002/adma.202001146.

165. Meng X, Chen L, Lv R, Liu M, He N, Wang Z. A metal–phenoic network-based multifunctional nanocomposite with pH-responsive ROS generation and drug release for synergistic chemodynamic/photothermal chemotherapy. J Mater Chem B. 2020(10):2177–88. https://doi.org/10.1039/DOTB00008F.

166. Liu F, Lin L, Zhang Y, Wang Y, Sheng S, Xu C, Tian H, Chen X. A tumor-microenvironment-activated nanovaccine-mediated theranostic nanoreactor for imaging-guided combined tumor therapy. Adv Mater. 2019;31(40):e1902885. https://doi.org/10.1002/adma.201902885.

167. Fan L, Xu X, Zhu C, Han J, Gao L, Li J, Guo R. Tumor catalytic-photothermal therapy with yolk-shell gold@carbon nanomides. ACS Appl Mater Interfaces. 2018;10(5):4502–11. https://doi.org/10.1021/acsami.7b17196.

168. Liu G, Zhu J, Guo H, Sun A, Chen P, Li X, Huang W, Song X, Dong X, MoC2-derivated polyoxometalate for NIR-II photostimulated imaging-guided chemodynamic/photothermal synergistic therapy. Angew
214. Ni K, Aung T, Li S, Fatuzzo N, Liang X, Lin W. Nanoscale metal-organic frameworks potentiate sonodynamic therapy via reshaping tumor microenvironment and facilitating electron-hole pair separation. Adv Funct Mater. 2020;30(27):10. https://doi.org/10.1002/adfm.202003262.

215. Lin X, Song J, Chen X, Yang H. Ultrasound-activated sensitizers and applications. Angew Chem Int Ed. 2020;59(34):14212–33. https://doi.org/10.1002/anie.202006823.

216. Xu B, Cui Y, Wang W, Li S, Lyu C, Wang S, Bao W, Wang H, Liu Y, Zhou Y, Hu J, Fan H. Graphene oxide-gated magnetic nanorons mediated magnetothermodynamic therapy favoring reactive oxygen species-related immune response for enhanced antitumor efficacy. ACS Nano. 2020;14(2):1936–50. https://doi.org/10.1021/acsnano.9b08320.

217. Hauser AK, Mitov MI, Daley EF, McGarry RC, Anderson KW, Hilt JZ. Targeted iron oxide nanoparticles for the enhancement of radiation therapy. Biomaterials. 2016;105:127–35. https://doi.org/10.1016/j.biomaterials.2016.07.032.

218. Shen J, Rees TW, Zhou Z, Yang S, Ji L, Chao H. A mitochondria-targeting magnetothermogenic nanozyme for magnet-induced synergistic cancer therapy. Biomaterials. 2020;251:120079. https://doi.org/10.1016/j.biomaterials.2020.120079.

219. Ying W, Zhang Y, Gao W, Cai X, Wang G, Wu X, Chen L, Meng Z, Zheng Y, Hu B, Lin X. Hollow magnetic nanocatalysts drive starvation–chemodynamic–hyperthermia synergistic therapy for tumor. ACS Nano. 2020;14(8):9662–74. https://doi.org/10.1021/acsnano.0c00910.

220. Liu X, Yan B, Li Y, Ma X, Jiao W, Shi K, Zhang T, Chen S, He Y, Liang X-J. Nanozymes-mediated hyperthermia synergistic therapy for cancer treatment. ACS Nano. 2020;14(12):1936–50. https://doi.org/10.1021/acsnano.9b08320.

221. Zhang W, Wang F, Hu C, Gao H, Hu J. The progress and perspectives of nanoparticle-enabled tumor metastasis treatment. Acta Pharm Sin B. 2020;10(11):2037–53. https://doi.org/10.1016/j.apsbps.2020.07.013.

222. Jiang Q, Wang K, Zhang X, Ouyang B, Liu H, Pang Z, Yang W. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-mediated local no release for inhibiting cancer-associated cell proliferation. Biomaterials. 2020;251:120079. https://doi.org/10.1016/j.biomaterials.2020.120079.

223. Xie C, Cen D, Ren Z, Wang Y, Wu Y, Li X, Han G, Cai X. FeS@BSA nanoclusters to enable H2S-amplified ros-based therapy with MRI guidance. Adv Sci. 2020;7(7):1903512. https://doi.org/10.1002/advs.201903512.

224. Wang X-S, Zeng J-Y, Li M-J, Li Q-R, Gao F, Zhang X-Z. Highly stable iron oxide/mesoporous silica shell nanocomposites. ACS Appl Bio Mater. 2020;3(3):1690–7. https://doi.org/10.1021/acsabm.9b01244.

225. Zhang C, Liu Y, Hu B, Liang K, He G, Chen Q, Wang Q, Chen H. Photothermal-promoted nanocatalysis combined with H2S-mediated respiration inhibition for efficient cancer therapy. Adv Funct Mater. 2021;31(8):2007991. https://doi.org/10.1002/adfm.202007991.

226. Yue W, Zhang H, Zhou Y, Ge W, Ren Y, Tan Z, Zhang M, Tang Z, Liu Y, Zhang L, Wu Y, Jiang X, Bu W. Structure-oriented catalytic radiosensitization for cancer radiotherapy. Nano Today. 2020;35:100988. https://doi.org/10.1016/j.nantod.2020.100988.

227. Hu Y, Lv T, Ma Y, Xu J, Zhang Y, Hou Y, Huang Z, Yin J. Nanoscale coordination polymers for synergistic no and chemodynamic therapy of liver cancer. Nanoscale. 2019;11(19):7336–47. https://doi.org/10.1039/c9nr03512b.

228. Ma Z, Liu S, Ke Y, Wang H, Chen R, Xiang Z, Xie Z, Shi Q, Yin J. Biomimetic nano-nos mediated local no release for inhibiting cancer-associated platelet activation and disrupting tumor vascular barriers. Biomaterials. 2020;255:306. https://doi.org/10.1016/j.biomaterials.2020.120141.

229. Hu Y, Lv T, Ma Y, Xu J, Zhang Y, Hou Y, Huang Z, Yin J. Nanoscale coordination polymers for synergistic no and chemodynamic therapy of liver cancer. Nano Lett. 2019;19(4):2731–38. https://doi.org/10.1021/acs.nanolett.9b01093.

230. Wang X-S, Zeng J-Y, Li M-J, Li Q-R, Gao F, Zhang X-Z. Highly stable iron carbonyl complex delivery nanosystem for improving cancer therapy. ACS Nano. 2020;14(8):9848–60. https://doi.org/10.1021/acsnano.0c00526.

231. Liu S, Wang L, Lin M, Wang D, Song Z, Li S, Ge R, Zhang X, Liu Y, Li Z, Sun H, Yang B, Zhang H. CuII-doped polydopamine-coated gold nanorods for tumor theranostics. ACS Appl Mater Interfaces. 2017;9(5):42493–306. https://doi.org/10.1021/acsami.7b03643.

232. An L, Cao M, Zhang X, Lin J, Tian Q, Yang S. Ph and glutathione synergistically triggered release and self-assembly of Au nanospheres for tumor theranostics. ACS Appl Mater Interfaces. 2020;12(7):8050–61. https://doi.org/10.1021/acsami.9b03002.

233. Fang W, Zhu W, Chen H, Zhang H, Hong S, Wei W, Zhao T. MRI enhancement and tumor targeted drug delivery using Zn++-doped FeOx core/mesoporous silica shell nanocomposites. ACS Appl Bio Mater. 2020;3(3):1690–70. https://doi.org/10.1021/acsabm.9b01244.

234. Zhao Y, Ye F, Brismar TB, Li X, He R, Heuchel R, El-Sayed R, Feliu N, Zheng W, Oerther S, Dutta J, Paraj WJ, Mammad M, Hassan M. Multimodal imaging of pancreatic ductal adenocarcinoma using multifunctional nanoparticles as contrast agents. ACS Appl Mater Interfaces. 2020;12(48):53665–81. https://doi.org/10.1021/acsami.0c15430.

235. Suárez-García S, Arias-Ramos N, Frías C, Candioti AP, Arius C, Lorenzo J, Ruiz-Molina D, Novio F. Dual T1/T2 nanoscale coordination polymers as...
novel contrast agents for MRI: A preclinical study for brain tumor. ACS Appl Mater Interfaces. 2018;10(45):38819–32. https://doi.org/10.1021/acsami.8b15594.

236. Dong L, Zhang P, Lei P, Song S, Xu X, Du K, Feng J, Zhang H. PEGylated GdF₂O₄ Fe nanoparticles as multimodal T₁/T₂-weighted MRI and X-ray CT imaging contrast agents. ACS Appl Mater Interfaces. 2017;9(24):20426–34. https://doi.org/10.1021/acsami.7b04438.

237. Chen J, Wang X, Zhang Y, Zhang H, Liu H, Zhang J, Feng H, Li B, Wu X, Gao Y, Yang B. A redox-triggered C-centered free radicals nanogenerator for self-enhanced magnetic resonance imaging and chemodynamic therapy. Biomaterials. 2021;266:120457. https://doi.org/10.1016/j.biomaterials.2020.120457.

238. Tang Z, Zhang H, Liu Y, Ni D, Zhang H, Jiao Y, He M, Shi J, Bu W. Antiferromagnetic pyrite as the tumor microenvironment-mediated nanoplatform for self-enhanced tumor imaging and therapy. Adv Mater. 2017. https://doi.org/10.1002/adma.201710683.

239. Yu J, Zhao F, Gao W, Yang X, Ju Y, Zhao L, Guo W, Xie J, Liang X-J, Tao X, Li J, Ying Y, Li W, Zheng J, Gao L, Xiong S, Mou X, Che S, Hou Y. Magnetic reactive oxygen species nanoreactor for switchable magnetic resonance imaging guided cancer therapy based on pH-sensitive Fe₃C@Fe₃O₄ nanoparticles. ACS Nano. 2019;13(9):10002–14. https://doi.org/10.1021/acsnano.9b07140.

240. Wang Z, Li Z, Sun Z, Wang S, Ali Z, Zhu S, Li S, Ren Q, Sheng F, Wang B, Hou Y. Visualization nanocarrier based on tumor microenvironment "unlocking" for intensive combination therapy of breast cancer. Sci Adv. 2020;6(48):eabc8733. https://doi.org/10.1126/sciadv.abc8733.

241. Ko J, Bhagwat N, Yee SS, Ortiz N, Sahmoud A, Black T, Aiello NM, Issadore D. Combining machine learning and nanofluidic technologies to diagnose pancreatic cancer using exosomes. ACS Nano. 2017;11(11):11892–93. https://doi.org/10.1021/acsnano.7b05505.

242. Tsvirkun D, Ben-Nun Y, Merquiol E, Zlotver I, Meir K, Weiss-Sadon T, Matok I, Popovtzer R, Blum G. CT imaging of enzymatic activity in cancer using covalent probes reveal a size-dependent pattern. J Am Chem Soc. 2018;140(38):12010–20. https://doi.org/10.1021/jacs.8b08717.

243. Cai P, Su D, Wang Y, He Z, Zhang C, Liu H, Liu Z, Zhang X, Gao L, Liu Y, Jiang H, Gao F, Gao X. Inherently PET/CT dual modality imaging lipid nanocapsules for early detection of orthotopic lung tumors. ACS Appl Bio Mater. 2020;3(1):611–21. https://doi.org/10.1021/acsabm.9b00993.

244. Zhang J, Li C, Zhang X, Huo S, Jin S, An F-F, Wang X, Xue X, Okeke CI, Hang L, Li H, Zhang T, Zhang S, Zhao Y, Song S, Li C, Zhu J, Yang Y, Zhang H. One-dimensional Fe₃P acts as a fenton agent in response to NIR ii light and ultrasound for deep tumor synergetic theranostics. Angew Chem Int Ed. 2019;58(8):2407–12. https://doi.org/10.1002/anie.201813702.

245. Wang J, Liang D, Jin Q, Feng J, Tang X. Bioorthogonal sers nanotags as a precision theranostic platform for in vivo sers imaging and cancer photothermal therapy. Bioconjug Chem. 2020;31(2):182–93. https://doi.org/10.1021/acs.bioconjchem.9b00022.

246. Dong S, Wang Y, Liu Z, Zhang W, Yi K, Zhang X, Zhang C, Yang C, Wang F, Xiao X. Beehive-inspired macroporous sers probe for cancer detection through capturing and analyzing exosomes in plasma. ACS Appl Mater Interfaces. 2020;12(4):5136–46. https://doi.org/10.1021/acsamatinterfaces.9b01332.

247. Cui K, Fan C, Chen G, Qiu Y, Li M, Lin M, Wan J-B, Cai C, Xiao Z. Parainmothiophenol radical reaction-functionalized gold nanoprobe for one-to-all detection of five reactive oxygen species in vivo. Anal Chem. 2018;90(20):12334–47. https://doi.org/10.1021/acs.analchem.8b03116.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.